ID,Violation Code,Short Description,State,City,Zip,Country,Fiscal Year,Project Area,Inspection Classification,Facility Name,Inspection End Date,Month,Day,Year,Long Description
1085911,21 CFR 211.67(b),Written procedures not established/followed,California,Foster City,94404,United States,2019,Drug Quality Assurance,NAI,Aurohealth LLC,4/11/2019,4,11,2019,"Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product."
1077356,21 CFR 314.80(c)(2),Late submission of quarterly safety reports,New Jersey,Somers Point,8244,United States,2019,Bioresearch Monitoring,NAI,"Rising Pharmaceuticals, Inc.",1/28/2019,1,28,2019,Not all quarterly periodic adverse drug experience reports have been submitted within 30 days of the close of the quarter.
1075479,21 CFR 211.22(d),"Procedures not  in writing, fully followed",New Jersey,Florham Park,7932,United States,2019,Postmarket Surv. and Epidemiology,NAI,Baxter Healthcare Corporation,12/21/2018,12,21,2018,The responsibilities and procedures applicable to the quality control unit are not fully followed.
1075479,21 CFR 211.58,Buildings not maintained in good state of repair,Kentucky,Lexington,40509,United States,2019,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,12/21/2018,12,21,2018,Buildings used in the manufacturing and processing of a drug product are not maintained in a good state of repair.
1075479,21 CFR 211.67(c),Cleaning/maintenance records not kept,Texas,Dallas,75235,United States,2019,Bioresearch Monitoring,VAI,Baxter Healthcare Corporation,12/21/2018,12,21,2018,Records are not kept for the cleaning of equipment.
1075479,21 CFR 211.100(a),Absence of Written Procedures,Florida,Palm Springs,33461,United States,2019,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,12/21/2018,12,21,2018,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
1075479,21 CFR 211.166(a),Written program not followed,Tennessee,Memphis,38119,United States,2019,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,12/21/2018,12,21,2018,The written stability testing program is not followed.
1075479,21 CFR 211.166(a)(1),Sample size - test intervals,New York,New York,10065,United States,2019,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,12/21/2018,12,21,2018,The written stability program for drug products does not include test intervals based on statistical criteria for each attribute examined to assure valid estimates of stability.
1075479,21 CFR 211.192,"Investigations of discrepancies, failures",Michigan,Ann Arbor,48109,United States,2019,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,12/21/2018,12,21,2018,There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
1073956,21 CFR 211.25(a),GMP Training Frequency,Minnesota,Northfield,55057,United States,2019,Drug Quality Assurance,NAI,L'Oreal USA Products Inc,11/29/2018,11,29,2018,GMP training is not conducted with sufficient frequency to assure that employees remain familiar with CGMP requirements applicable to them.
1073956,21 CFR 211.165(b),Microbiological testing,Indiana,Crown Point,46307,United States,2019,Drug Quality Assurance,NAI,L'Oreal USA Products Inc,11/29/2018,11,29,2018,Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
1073956,21 CFR 211.170(b),Annual visual exams of drug products,Florida,Tampa,33647,United States,2019,Bioresearch Monitoring,NAI,L'Oreal USA Products Inc,11/29/2018,11,29,2018,Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
1073956,21 CFR 211.194(a)(1),Description and Identification of Samples,Texas,Dallas,75390,United States,2019,Bioresearch Monitoring,NAI,L'Oreal USA Products Inc,11/29/2018,11,29,2018,Laboratory records are deficient in that they do not include a quantity and date sample taken.
1070336,21 CFR 211.113(b),Procedures for sterile drug products,Connecticut,Groton,6340,United States,2019,Bioresearch Monitoring,NAI,Merck Sharp & Dohme Corp.,10/30/2018,10,30,2018,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
1069929,21 CFR 211.188(b)(5),In-process and laboratory control results,California,San Diego,92123,United States,2019,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,10/24/2018,10,24,2018,Batch production and control records do not include in-process results for each batch of drug product produced.
1065227,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Utah,Salt Lake City,84112,United States,2018,Drug Quality Assurance,VAI,GlaxoSmithKline LLC,9/11/2018,9,11,2018,The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
1065227,21 CFR 211.110(a),Control procedures to monitor and validate performance,Tennessee,Knoxville,37921,United States,2018,Drug Quality Assurance,NAI,GlaxoSmithKline LLC,9/11/2018,9,11,2018,Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
1057924,21 CFR 211.192,"Investigations of discrepancies, failures",California,Inglewood,90305,United States,2018,Bioresearch Monitoring,VAI,"Genentech, Inc.",7/5/2018,7,5,2018,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
1058302,21 CFR 314.80(c)(1)(i),Late submission of 15-day report,Colorado,Parker,80134,United States,2018,Drug Quality Assurance,VAI,AbbVie Inc.,7/2/2018,7,2,2018,Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
1049214,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Texas,Ennis,75119,United States,2018,Drug Quality Assurance,NAI,Guardian Pharmacy Services,4/20/2018,4,20,2018,The responsibilities and procedures applicable to the quality control unit are not fully followed.
1049214,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,California,Oceanside,92056,United States,2018,Bioresearch Monitoring,NAI,Guardian Pharmacy Services,4/20/2018,4,20,2018,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
1049214,21 CFR 211.42(c)(10)(v),Cleaning System,Maryland,Baltimore,21229,United States,2018,Bioresearch Monitoring,NAI,Guardian Pharmacy Services,4/20/2018,4,20,2018,Aseptic processing areas are deficient regarding the system for cleaning  and disinfecting the room and equipment to produce aseptic conditions.
1049214,21 CFR 211.46(c),Air recirculation of dust from production areas,Illinois,Oak Brook,60523,United States,2018,Drug Quality Assurance,NAI,Guardian Pharmacy Services,4/20/2018,4,20,2018,"Air is recirculated to production areas, without adequate measures to control recirculation of dust."
1049214,21 CFR 211.63,"Equipment Design, Size and Location",Florida,Brandon,33511,United States,2018,Bioresearch Monitoring,NAI,Guardian Pharmacy Services,4/20/2018,4,20,2018,"Equipment used in the manufacture, processing, packing or holding of  drug products is not of appropriate design to facilitate operations for its cleaning and maintenance."
1049214,21 CFR 211.113(b),Validation lacking for sterile drug products,Illinois,Peoria,61605,United States,2018,Bioresearch Monitoring,NAI,Guardian Pharmacy Services,4/20/2018,4,20,2018,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
1047915,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Texas,Houston,77024,United States,2018,Bioresearch Monitoring,VAI,Mylan Pharmaceuticals Inc.,4/12/2018,4,12,2018,The responsibilities and procedures applicable to the quality control unit are not fully followed.
1047915,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Ohio,Lima,45804,United States,2018,Drug Quality Assurance,NAI,Mylan Pharmaceuticals Inc.,4/12/2018,4,12,2018,"Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
1047915,21 CFR 211.67(b),Written procedures not established/followed,Iowa,Spencer,51301,United States,2018,Drug Quality Assurance,NAI,Mylan Pharmaceuticals Inc.,4/12/2018,4,12,2018,"Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product."
1047915,21 CFR 211.100(a),Absence of Written Procedures,Texas,Houston,77054,United States,2018,Bioresearch Monitoring,NAI,Mylan Pharmaceuticals Inc.,4/12/2018,4,12,2018,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
1047915,21 CFR 211.160(b),Scientifically sound laboratory controls,Pennsylvania,Warrington,18976,United States,2018,Drug Quality Assurance,OAI,Mylan Pharmaceuticals Inc.,4/12/2018,4,12,2018,"Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity."
1047915,21 CFR 211.170(b),Annual visual exams of drug products,Florida,Miramar,33025,United States,2018,Drug Quality Assurance,VAI,Mylan Pharmaceuticals Inc.,4/12/2018,4,12,2018,Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
1047915,21 CFR 211.192,"Investigations of discrepancies, failures",Ohio,Old Fort,44861,United States,2018,Drug Quality Assurance,VAI,Mylan Pharmaceuticals Inc.,4/12/2018,4,12,2018,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
1047915,21 CFR 211.198(b)(2),"Written record of complaint to include findings, follow-up",California,North Hills,91343,United States,2018,Drug Quality Assurance,OAI,Mylan Pharmaceuticals Inc.,4/12/2018,4,12,2018,Written records of investigation of a drug complaint do not include the follow-up.
1046205,21 CFR 211.103,Yield calculations not verified by 2nd person,Ohio,Cincinnati,45227,United States,2018,Bioresearch Monitoring,VAI,RemedyRepack Inc.,3/30/2018,3,30,2018,Yield calculations are not performed by one person and independently verified by a second person.
1046205,21 CFR 211.170(b)(1),Reserve sample retention time,Pennsylvania,Exton,19341,United States,2018,Bioresearch Monitoring,NAI,RemedyRepack Inc.,3/30/2018,3,30,2018,The retention period for drug product reserve samples (except those described in 211.170(b)(2) and (3)) is deficient in that they are not retained for one year after the expiration date of the drug product.
1045988,21 CFR 211.84(d)(2),Component written specification,Ohio,Columbus,43210,United States,2018,Bioresearch Monitoring,VAI,Cantrell Drug Company,3/22/2018,3,22,2018,"Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality."
1045988,21 CFR 211.113(b),Procedures for sterile drug products,Georgia,Conyers,30013,United States,2018,Drug Quality Assurance,OAI,Cantrell Drug Company,3/22/2018,3,22,2018,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
1045988,21 CFR 211.192,"Extent of discrepancy, failure  investigations",Colorado,Denver,80209,United States,2018,Bioresearch Monitoring,NAI,Cantrell Drug Company,3/22/2018,3,22,2018,Investigations of an unexplained discrepancy did not extend to other drug products that may have been associated with the specific failure or discrepancy.
1045988,21 CFR 211.198(a),Adverse Drug Experience,North Carolina,Durham,27705,United States,2018,Bioresearch Monitoring,NAI,Cantrell Drug Company,3/22/2018,3,22,2018,Complaint procedures are deficient in that they do not include provisions that allow for the review to determine if the complaints represent serious and unexpected adverse drug experiences which are required to be reported to FDA.
1043676,21 CFR 211.160(a),Following/documenting laboratory controls,California,Palm Desert,92260,United States,2018,Bioresearch Monitoring,VAI,"Sun Pharmaceutical Industries, Inc.",3/9/2018,3,9,2018,Established standards are not followed.
1043676,21 CFR 211.192,"Investigations of discrepancies, failures",Texas,Houston,77054,United States,2018,Postmarket Surv. and Epidemiology,VAI,"Sun Pharmaceutical Industries, Inc.",3/9/2018,3,9,2018,There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
1043676,21 CFR 211.192,Written record of investigation incomplete,New York,Albany,12208,United States,2018,Bioresearch Monitoring,NAI,"Sun Pharmaceutical Industries, Inc.",3/9/2018,3,9,2018,Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
1043109,21 CFR 211.68(a),Calibration/Inspection/Checking not done,Pennsylvania,Hershey,17033,United States,2018,Bioresearch Monitoring,NAI,"Lannett Company, Inc.",2/28/2018,2,28,2018,Routine checking of equipment is not performed according to a written program designed to assure proper performance.
1041728,21 CFR 211.100(a),Approval and review of procedures,Puerto Rico,Las Piedras,771,United States,2018,Drug Quality Assurance,VAI,Carilion Materials Management,2/14/2018,2,14,2018,Written procedures are not reviewed and approved by the quality control unit.
1041728,21 CFR 211.192,No written record of investigation,New York,Central Islip,11722,United States,2018,Drug Quality Assurance,NAI,Carilion Materials Management,2/14/2018,2,14,2018,Written records are not made of investigations into unexplained discrepancies.
1041728,21 CFR 211.204,Record information inclusions,Texas,Dallas,75390,United States,2018,Bioresearch Monitoring,VAI,Carilion Materials Management,2/14/2018,2,14,2018,"Records of returned drug products do not include the lot, control or batch number, reason for return, date of disposition and ultimate disposition."
1039982,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Ohio,Streetsboro,44241,United States,2018,Drug Quality Assurance,VAI,Natural Health Supply,2/6/2018,2,6,2018,The responsibilities and procedures applicable to the quality control unit are not in writing.
1039982,21 CFR 211.100(a),Absence of Written Procedures,Illinois,Wood Dale,60191,United States,2018,Drug Quality Assurance,OAI,Natural Health Supply,2/6/2018,2,6,2018,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
1039982,21 CFR 211.160(a),Deviations from laboratory control requirements,Georgia,Decatur,30030,United States,2018,Bioresearch Monitoring,NAI,Natural Health Supply,2/6/2018,2,6,2018,"Deviations from written specifications, standards and test procedures are not recorded and justified."
1039982,21 CFR 211.186(a),Written procedures followed,New Jersey,Woodcliff Lake,7677,United States,2018,Postmarket Surv. and Epidemiology,NAI,Natural Health Supply,2/6/2018,2,6,2018,Procedures for the preparation of master production and control records are not described in a written procedure.
1031577,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Mississippi,Port Gibson,39150,United States,2018,Bioresearch Monitoring,NAI,The Procter & Gamble Manufacturing Company,11/17/2017,11,17,2017,"Equipment and utensils are not maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
1031577,21 CFR 211.198(a),Complaint Handling Procedure,New Jersey,Florence,8518,United States,2018,Drug Quality Assurance,NAI,The Procter & Gamble Manufacturing Company,11/17/2017,11,17,2017,Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.
1031655,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Utah,South Ogden,84405,United States,2018,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,11/17/2017,11,17,2017,The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
1031655,21 CFR 211.58,Buildings not maintained in good state of repair,Texas,San Antonio,78212,United States,2018,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,11/17/2017,11,17,2017,Buildings used in the manufacturing of a drug product are not maintained in a good state of repair.
1031655,21 CFR 211.188(b),Batch production and Batch Control Record Requirements,Minnesota,Eden Prairie,55344,United States,2018,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,11/17/2017,11,17,2017,"The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing, processing, packing and holding."
1031655,21 CFR 211.192,"Investigations of discrepancies, failures",New York,Amsterdam,12010,United States,2018,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,11/17/2017,11,17,2017,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
1029306,21 CFR 211.166(a),"Results not used for expiration dates, storage cond.",New Jersey,Branchburg,8876,United States,2017,Drug Quality Assurance,NAI,Aidarex Pharmaceuticals LLC,10/20/2017,10,20,2017,Results of stability testing are not used in determining appropriate storage conditions and expiration dates.
1017861,21 CFR 211.25(a),"Training , Education , Experience overall",Connecticut,Meriden,6450,United States,2017,Drug Quality Assurance,NAI,Boiron,7/7/2017,7,7,2017,Employees  engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.
1017861,21 CFR 211.142(b),Storage under appropriate conditions,New Jersey,Oakhurst,7755,United States,2017,Drug Quality Assurance,NAI,Boiron,7/7/2017,7,7,2017,"Drug products are not stored under appropriate conditions of temperature and humidity so that their identity, strength, quality, and purity are not affected."
1017861,21 CFR 211.166(c)(1),"Homeopathic drugs, assessment of stability",Tennessee,Memphis,38141,United States,2017,Drug Quality Assurance,NAI,Boiron,7/7/2017,7,7,2017,There is no written assessment of stability of homeopathic drug products based at least on testing or examination of the drug product for compatibility of the ingredients and marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use.
1017861,21 CFR 211.194(a)(4),Complete Test Data,Wyoming,Green River,82935,United States,2017,Drug Quality Assurance,NAI,Boiron,7/7/2017,7,7,2017,"Laboratory records are deficient in that they do not include a complete record of all data obtained during testing. Electronic records are used, but they do not meet requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records."
1016395,21 CFR 211.22(a),"Authority lacking to review records, investigate errors",Texas,Dallas,75247,United States,2017,Drug Quality Assurance,NAI,Cantrell Drug Company,6/29/2017,6,29,2017,The quality control unit lacks authority  to fully investigate errors that have occurred.
1016395,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Texas,Houston,77030,United States,2017,Bioresearch Monitoring,NAI,Cantrell Drug Company,6/29/2017,6,29,2017,The responsibilities and procedures applicable to the quality control unit are not fully followed.
1016395,21 CFR 211.113(b),Procedures for sterile drug products,Texas,Houston,77081,United States,2017,Bioresearch Monitoring,NAI,Cantrell Drug Company,6/29/2017,6,29,2017,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
1016395,21 CFR 211.192,"Investigations of discrepancies, failures",Pennsylvania,Sharon Hill,19079,United States,2017,Drug Quality Assurance,NAI,Cantrell Drug Company,6/29/2017,6,29,2017,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
1016636,21 CFR 211.67(b),Written procedures fail to include,Indiana,Bloomington,47403,United States,2017,Drug Quality Assurance,VAI,Cardinal Health,6/29/2017,6,29,2017,Written procedures for cleaning and maintenance fail to include parameters relevant to the operation.
1016636,21 CFR 211.188(a),Accurate reproduction,Illinois,Deerfield,60015,United States,2017,Postmarket Surv. and Epidemiology,VAI,Cardinal Health,6/29/2017,6,29,2017,The batch production and control records are deficient in that they are not an accurate reproduction of the appropriate master production or control record.
1015801,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Florida,Aventura,33180,United States,2017,Unapproved and Misbranded Drugs,OAI,American Health Packaging,6/15/2017,6,15,2017,The responsibilities and procedures applicable to the quality control unit are not fully followed.
1015801,21 CFR 211.100(b),SOPs not followed / documented,Florida,South Miami,33143,United States,2017,Bioresearch Monitoring,VAI,American Health Packaging,6/15/2017,6,15,2017,Written production and process control procedures are not followed in the execution of production and process control functions.
1015801,21 CFR 211.198(a),Procedures to be written and followed,Florida,Tampa,33612,United States,2017,Bioresearch Monitoring,NAI,American Health Packaging,6/15/2017,6,15,2017,Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.
1014399,21 CFR 211.67(b)(2),Cleaning SOPs/schedules,Minnesota,Saint Paul,55107,United States,2017,Drug Quality Assurance,NAI,Apotex Inc.,6/14/2017,6,14,2017,"Procedures for the cleaning and maintenance of equipment are deficient regarding maintenance and cleaning schedules, including, where appropriate, sanitizing schedules."
1014399,21 CFR 211.68(b),Backup file not maintained,California,Irvine,92618,United States,2017,Drug Quality Assurance,VAI,Apotex Inc.,6/14/2017,6,14,2017,Failure to maintain a backup file of data entered into the computer or related system.
1032447,21 CFR 314.80(b),Failure to develop written procedures,Maryland,Silver Spring,20910,United States,2017,Drug Quality Assurance,VAI,Walgreen Company,5/19/2017,5,19,2017,"Written procedures have not been developed for the surveillance, receipt, evaluation and reporting to FDA of post marketing adverse drug experiences."
1005521,21 CFR 211.188(b)(11),Identification of Persons Performing Significant Steps,Florida,Aventura,33180,United States,2017,Bioresearch Monitoring,NAI,"Sun Pharmaceutical Industries, Inc.",3/20/2017,3,20,2017,The batch production and control records are deficient in that they do not include identification of persons performing each significant step in the operation.
998830,21 CFR 211.22(a),Lack of quality control unit,Utah,Sandy,84070,United States,2017,Drug Quality Assurance,NAI,"TG United, Inc.",1/25/2017,1,25,2017,There is no quality control unit.
998830,21 CFR 211.63,"Equipment Design, Size and Location",Florida,Dania,33004,United States,2017,Drug Quality Assurance,VAI,"TG United, Inc.",1/25/2017,1,25,2017,"Equipment used in the manufacture, processing, packing or holding of  drug products is not of appropriate design to facilitate operations for its intended use."
998830,21 CFR 211.84(d)(1),Component identity verification,California,Rancho Cordova,95670,United States,2017,Drug Quality Assurance,VAI,"TG United, Inc.",1/25/2017,1,25,2017,Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.
998830,21 CFR 211.84(d)(2),Establish reliability of supplier's C of A,Missouri,North Kansas City,64116,United States,2017,Drug Quality Assurance,NAI,"TG United, Inc.",1/25/2017,1,25,2017,Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
998830,21 CFR 211.100(a),Absence of Written Procedures,Missouri,Kansas City,64110,United States,2017,Drug Quality Assurance,NAI,"TG United, Inc.",1/25/2017,1,25,2017,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
998830,21 CFR 211.160(b),Scientifically sound laboratory controls,Connecticut,Milford,6460,United States,2017,Drug Quality Assurance,NAI,"TG United, Inc.",1/25/2017,1,25,2017,"Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, sampling plans and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity."
998830,21 CFR 211.165(b),Microbiological testing,Ohio,Saint Louisville,43071,United States,2017,Unapproved and Misbranded Drugs,NAI,"TG United, Inc.",1/25/2017,1,25,2017,Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
998830,21 CFR 211.166(b),Adequate number of batches on stability,California,Palo Alto,94304,United States,2017,Bioresearch Monitoring,NAI,"TG United, Inc.",1/25/2017,1,25,2017,An adequate number of batches of each drug product are not tested to determine an appropriate expiration date.
998830,21 CFR 211.198(a),Complaint Handling Procedure,California,Novato,94949,United States,2017,Bioresearch Monitoring,NAI,"TG United, Inc.",1/25/2017,1,25,2017,Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.
995279,21 CFR 211.194(a)(2),Suitability of testing methods verified,Florida,Lakeland,33805,United States,2016,Bioresearch Monitoring,NAI,"VistaPharm, Inc.",12/13/2016,12,13,2016,The suitability of all testing methods is not verified under actual conditions of use.
994523,21 CFR 211.160(b),Scientifically sound laboratory controls,Florida,Miami,33147,United States,2016,Bioresearch Monitoring,VAI,Mylan Pharmaceuticals Inc.,11/18/2016,11,18,2016,"Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity."
994523,21 CFR 211.165(e),Test methods,Wisconsin,La Crosse,54601,United States,2016,Bioresearch Monitoring,NAI,Mylan Pharmaceuticals Inc.,11/18/2016,11,18,2016,"The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented."
991454,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,South Carolina,Greenville,29611,United States,2016,Drug Quality Assurance,VAI,Guardian Pharmacy Services,10/21/2016,10,21,2016,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
990072,21 CFR 211.42(b),Adequate space lacking  to prevent mix-ups and contamination,South Carolina,Greenville,29605,United States,2016,Drug Quality Assurance,NAI,Cantrell Drug Company,10/14/2016,10,14,2016,"The building lacks adequate space for the orderly placement of equipment and materials to prevent mix-ups between different components, drug product containers, labeling, in-process materials and drug products and to prevent contamination."
990072,21 CFR 211.42(c)(10),Aseptic Processing Area,Illinois,Harvey,60426,United States,2016,Bioresearch Monitoring,NAI,Cantrell Drug Company,10/14/2016,10,14,2016,Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.
990072,21 CFR 211.42(c)(10)(iii),Air Supply,Tennessee,Memphis,38116,United States,2016,Drug Quality Assurance,NAI,Cantrell Drug Company,10/14/2016,10,14,2016,Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
990072,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,California,La Jolla,92093,United States,2016,Bioresearch Monitoring,OAI,Cantrell Drug Company,10/14/2016,10,14,2016,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
990072,21 CFR 211.42(c)(10)(v),Cleaning System,Pennsylvania,Folcroft,19032,United States,2016,Drug Quality Assurance,OAI,Cantrell Drug Company,10/14/2016,10,14,2016,Aseptic processing areas are deficient regarding the system for cleaning  and disinfecting the room and equipment to produce aseptic conditions.
990072,21 CFR 211.113(b),Procedures for sterile drug products,Oregon,Harrisburg,97446,United States,2016,Unapproved and Misbranded Drugs,VAI,Cantrell Drug Company,10/14/2016,10,14,2016,"Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed."
990072,21 CFR 211.165(a),Testing and release for distribution,California,Irvine,92618,United States,2016,Drug Quality Assurance,VAI,Cantrell Drug Company,10/14/2016,10,14,2016,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
990072,21 CFR 211.167(a),"Sterility/pyrogens - test methods written, followed",Puerto Rico,Barceloneta,617,United States,2016,Drug Quality Assurance,VAI,Cantrell Drug Company,10/14/2016,10,14,2016,Test procedures relative to appropriate laboratory testing for sterility and pyrogens are not written and followed.
990072,FDCA 503B(a)(10),"Drug product label, outsourcer facility",New York,Brooklyn,11235,United States,2016,Bioresearch Monitoring,NAI,Cantrell Drug Company,10/14/2016,10,14,2016,The labels of your outsourcing facilityÂ’s drug products are deficient.
988291,21 CFR 211.80(a),Procedures To Be in Writing,South Carolina,Florence,29501,United States,2016,Drug Quality Assurance,NAI,Sage Products Inc,9/1/2016,9,1,2016,"Written procedures are lacking which describe in sufficient detail the sampling , testing , approval and rejection of components , drug product containers and closures."
988291,21 CFR 211.84(d)(2),Establish reliability of supplier's C of A,Florida,Indian Harbour Beach,32937,United States,2016,Drug Quality Assurance,VAI,Sage Products Inc,9/1/2016,9,1,2016,Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
986013,21 CFR 211.28(a),Clothing appropriate for duties performed,Illinois,Elgin,60123,United States,2016,Drug Quality Assurance,VAI,"KRS Global Biotechnology, Inc",8/31/2016,8,31,2016,Clothing of personnel engaged in the manufacturing and processing of drug products is not  appropriate for the duties they perform.
986013,21 CFR 211.42(c)(10)(iii),Air Supply,Texas,Mesquite,75149,United States,2016,Drug Quality Assurance,VAI,"KRS Global Biotechnology, Inc",8/31/2016,8,31,2016,Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
986013,21 CFR 211.42(c)(10)(v),Cleaning System,Georgia,Kennesaw,30152,United States,2016,Drug Quality Assurance,NAI,"KRS Global Biotechnology, Inc",8/31/2016,8,31,2016,Aseptic processing areas are deficient regarding the system for cleaning  and disinfecting the room and equipment to produce aseptic conditions.
982487,21 CFR 211.22(a),"Authority lacking to review records, investigate errors",New Jersey,Colonia,7067,United States,2016,Drug Quality Assurance,OAI,"Genentech, Inc.",7/8/2016,7,8,2016,The quality control unit lacks authority  to fully investigate errors that have occurred.
988705,21 CFR 211.130(b),Unlabeled filled containers controls,New Jersey,Lakewood,8701,United States,2016,Drug Quality Assurance,VAI,"Fresenius Kabi USA, LLC",6/24/2016,6,24,2016,"Filled drug product containers which are set aside and held in an unlabeled condition are not identified and handled to preclude mislabeling of individual containers, lots or portions of lots."
975869,21 CFR 211.22(d),"Procedures not  in writing, fully followed",California,Northridge,91325,United States,2016,Bioresearch Monitoring,NAI,"Akorn, Inc.",6/10/2016,6,10,2016,The responsibilities and procedures applicable to the quality control unit are not fully followed.
975869,21 CFR 211.100(b),Procedure Deviations Recorded and Justified,Massachusetts,Maynard,1754,United States,2016,Postmarket Surv. and Epidemiology,VAI,"Akorn, Inc.",6/10/2016,6,10,2016,Deviations from written production and process control procedures are not recorded and justified.
975869,21 CFR 211.110(a),Control procedures to monitor and validate performance,New York,Farmingdale,11735,United States,2016,Drug Quality Assurance,VAI,"Akorn, Inc.",6/10/2016,6,10,2016,Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
975869,21 CFR 211.192,"Extent of discrepancy, failure  investigations",New Jersey,Fairfield,7004,United States,2016,Drug Quality Assurance,VAI,"Akorn, Inc.",6/10/2016,6,10,2016,Investigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other drug products that may have been associated with the specific failure or discrepancy.
975869,21 CFR 211.194(a)(2),Suitability of testing methods verified,Wisconsin,Prescott,54021,United States,2016,Drug Quality Assurance,VAI,"Akorn, Inc.",6/10/2016,6,10,2016,The suitability of all testing methods is not verified under actual conditions of use.
975839,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Oklahoma,Broken Arrow,74012,United States,2016,Drug Quality Assurance,VAI,"Genentech, Inc.",4/15/2016,4,15,2016,"Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
975839,21 CFR 211.113(b),Procedures for sterile drug products,Illinois,Chicago,60642,United States,2016,Drug Quality Assurance,NAI,"Genentech, Inc.",4/15/2016,4,15,2016,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
969547,21 CFR 211.63,"Equipment Design, Size and Location",Minnesota,Minneapolis,55401,United States,2016,Bioresearch Monitoring,NAI,Reliable Rexall-A Compounding Pharmacy,3/29/2016,3,29,2016,"Equipment used in the manufacture, processing, packing or holding of  drug products is not of appropriate design to facilitate operations for its intended use."
969547,21 CFR 211.125(a),Strict control not exercised over labeling issued,Wisconsin,Neenah,54956,United States,2016,Drug Quality Assurance,NAI,Reliable Rexall-A Compounding Pharmacy,3/29/2016,3,29,2016,Strict control is not exercised over labeling issued for use in drug product labeling operations.
969547,21 CFR 211.166(a),"Results not used for expiration dates, storage cond.",Kansas,Overland Park,66214,United States,2016,Drug Quality Assurance,NAI,Reliable Rexall-A Compounding Pharmacy,3/29/2016,3,29,2016,Results of stability testing are not used in determining expiration dates.
969547,21 CFR 211.204,"Associated batches implicated, investigated",South Carolina,Clinton,29325,United States,2016,Drug Quality Assurance,VAI,Reliable Rexall-A Compounding Pharmacy,3/29/2016,3,29,2016,No appropriate investigation was conducted when a returned drug product appeared to implicate associated batches of drug products.
967552,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,New Jersey,Fairfield,7004,United States,2016,Unapproved and Misbranded Drugs,OAI,Cadila Healthcare Limited,3/18/2016,3,18,2016,"Equipment and utensils are not maintained at appropriate intervals to  prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
967552,21 CFR 211.100(b),SOPs not followed / documented,New Hampshire,Charlestown,3603,United States,2016,Drug Quality Assurance,VAI,Cadila Healthcare Limited,3/18/2016,3,18,2016,Written production and process control procedures are not followed in the execution of production and process control functions.
967552,21 CFR 211.113(a),Procedures for non-sterile drug products,Minnesota,Rochester,55905,United States,2016,Drug Quality Assurance,VAI,Cadila Healthcare Limited,3/18/2016,3,18,2016,Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established.
965166,21 CFR 211.22(d),"Procedures not  in writing, fully followed",California,Livermore,94551,United States,2016,Drug Quality Assurance,OAI,"Pharmakon Pharmaceuticals, Inc.",3/16/2016,3,16,2016,The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
965166,21 CFR 211.28(a),Clothing appropriate for duties performed,New Jersey,Hamilton,8691,United States,2016,Drug Quality Assurance,NAI,"Pharmakon Pharmaceuticals, Inc.",3/16/2016,3,16,2016,Clothing of personnel engaged in the processing of drug products is not  appropriate for the duties they perform.
965166,21 CFR 211.42(c)(10)(iii),Air Supply,Alabama,Birmingham,35215,United States,2016,Bioresearch Monitoring,NAI,"Pharmakon Pharmaceuticals, Inc.",3/16/2016,3,16,2016,Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
965166,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Illinois,Schaumburg,60173,United States,2016,Drug Quality Assurance,NAI,"Pharmakon Pharmaceuticals, Inc.",3/16/2016,3,16,2016,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
965166,21 CFR 211.94(c),"Containers & Closures Clean, Sterilized, Pyrogen-free",Oregon,Portland,97203,United States,2016,Drug Quality Assurance,NAI,"Pharmakon Pharmaceuticals, Inc.",3/16/2016,3,16,2016,Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
965166,21 CFR 211.165(a),Testing and release for distribution,California,Torrance,90503,United States,2016,Drug Quality Assurance,NAI,"Pharmakon Pharmaceuticals, Inc.",3/16/2016,3,16,2016,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
965166,21 CFR 211.167(a),Sterility/pyrogen-free testing,Georgia,Winder,30680,United States,2016,Drug Quality Assurance,VAI,"Pharmakon Pharmaceuticals, Inc.",3/16/2016,3,16,2016,Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
965166,21 CFR 211.192,"Investigations of discrepancies, failures",Massachusetts,Billerica,1821,United States,2016,Bioresearch Monitoring,NAI,"Pharmakon Pharmaceuticals, Inc.",3/16/2016,3,16,2016,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
969544,21 CFR 211.25(a),"Training , Education , Experience overall",Pennsylvania,Quakertown,18951,United States,2016,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,2/26/2016,2,26,2016,"Employees  engaged in the manufacture , processing and packing of a drug product lack the training required to perform their assigned functions."
969544,21 CFR 211.56(a),"Sanitation--buildings not clean, free of infestation",Louisiana,Shreveport,71106,United States,2016,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,2/26/2016,2,26,2016,"Buildings used in the manufacture, processing, packing or holding of drug products are not free of infestation by rodents, birds insects, and other vermin."
969544,21 CFR 211.113(b),Procedures for sterile drug products,Iowa,Coralville,52241,United States,2016,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,2/26/2016,2,26,2016,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
969544,21 CFR 211.192,"Investigations of discrepancies, failures",Washington,Woodinville,98072,United States,2016,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,2/26/2016,2,26,2016,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
962308,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Arkansas,El Dorado,71730,United States,2016,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",2/4/2016,2,4,2016,The responsibilities and procedures applicable to the quality control unit are not fully followed.
962308,21 CFR 211.25(a),"Training , Education , Experience overall",Michigan,Lansing,48917,United States,2016,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",2/4/2016,2,4,2016,Employees engaged in the manufacture of a drug product lack the training required to perform their assigned functions.
962308,21 CFR 211.192,"Investigations of discrepancies, failures",Utah,Layton,84041,United States,2016,Bioresearch Monitoring,VAI,"Fresenius Kabi USA, LLC",2/4/2016,2,4,2016,There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
962308,21 CFR 211.192,Quality control unit review of records,Nevada,Las Vegas,89119,United States,2016,Bioresearch Monitoring,VAI,"Fresenius Kabi USA, LLC",2/4/2016,2,4,2016,"Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed."
959102,21 CFR 211.28(a),Protective Apparel Not Worn,New Jersey,Hackensack,7601,United States,2015,Drug Quality Assurance,NAI,"Abbott's Compounding Pharmacy, Inc.",1/8/2016,1,8,2016,Protective apparel is not worn as necessary to protect drug products from contamination.
959102,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Illinois,Melrose Park,60160,United States,2015,Drug Quality Assurance,NAI,"Abbott's Compounding Pharmacy, Inc.",1/8/2016,1,8,2016,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
959102,21 CFR 211.113(b),Procedures for sterile drug products,New Jersey,Hackensack,7601,United States,2015,Bioresearch Monitoring,VAI,"Abbott's Compounding Pharmacy, Inc.",1/8/2016,1,8,2016,"Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established , written and followed ."
956397,21 CFR 211.166(a),"Results not used for expiration dates, storage cond.",Massachusetts,Quincy,2169,United States,2015,Bioresearch Monitoring,NAI,"Pharmedium Services, LLC",1/4/2016,1,4,2016,Results of stability testing are not used in determining expiration dates .
956397,21 CFR 211.167(a),Sterility/pyrogen-free testing,Virginia,Newport News,23602,United States,2015,Bioresearch Monitoring,VAI,"Pharmedium Services, LLC",1/4/2016,1,4,2016,Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
956397,21 CFR 211.192,"Extent of discrepancy, failure  investigations",Ohio,Poland,44514,United States,2015,Drug Quality Assurance,VAI,"Pharmedium Services, LLC",1/4/2016,1,4,2016,Investigations of an unexplained discrepancy and a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy .
955661,21 CFR 211.25(a),"Training , Education , Experience overall",Kentucky,Richmond,40475,United States,2015,Drug Quality Assurance,NAI,"PD-Rx Pharmaceuticals, Inc.",12/4/2015,12,4,2015,Employees  engaged in the manufacture and processing and packing and holding of a drug product lack the training and experience required to perform their assigned functions.
955661,21 CFR 211.63,"Equipment Design, Size and Location",California,Corona,92879,United States,2015,Drug Quality Assurance,OAI,"PD-Rx Pharmaceuticals, Inc.",12/4/2015,12,4,2015,"Equipment used in the manufacture, processing, packing or holding of  drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance ."
955661,21 CFR 211.125(a),Strict control not exercised over labeling issued,Pennsylvania,Fort Washington,19034,United States,2015,Drug Quality Assurance,NAI,"PD-Rx Pharmaceuticals, Inc.",12/4/2015,12,4,2015,Strict control is not exercised over labeling issued for use in drug product labeling operations.
955661,21 CFR 211.198(a),Complaint Handling Procedure,Tennessee,Bristol,37620,United States,2015,Drug Quality Assurance,VAI,"PD-Rx Pharmaceuticals, Inc.",12/4/2015,12,4,2015,Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed .
953897,21 CFR 211.68(b),Written record not kept of program and validation data,Connecticut,Hamden,6517,United States,2015,Bioresearch Monitoring,OAI,RemedyRepack Inc.,11/23/2015,11,23,2015,A written record of the program along with appropriate validation data has not been maintained in situations where backup data is eliminated by computerization or other automated processes.
953897,21 CFR 211.111,Establishment of time limitations,Texas,Dallas,75234,United States,2015,Drug Quality Assurance,OAI,RemedyRepack Inc.,11/23/2015,11,23,2015,Time limits are not established when appropriate  for the completion of each production phase to assure the quality of the drug product.
953897,21 CFR 211.130,"Procedures are written, and followed",New York,New York,10016,United States,2015,Bioresearch Monitoring,NAI,RemedyRepack Inc.,11/23/2015,11,23,2015,Procedures designed to assure that correct labels and labeling are used for drug products are not written .
953897,21 CFR 211.170(b)(1),"Retention time of reserve samples, in general",New York,New York,10016,United States,2015,Bioresearch Monitoring,NAI,RemedyRepack Inc.,11/23/2015,11,23,2015,Reserve samples for drug products are not retained for one year after the expiration date of the drug product.
953897,21 CFR 211.186(a),Written procedures followed,New Jersey,Berkeley Heights,7922,United States,2015,Postmarket Surv. and Epidemiology,VAI,RemedyRepack Inc.,11/23/2015,11,23,2015,Procedures for the preparation of master production and control records are not described in a written procedure .
953897,21 CFR 211.192,No written record of investigation,Indiana,Lafayette,47909,United States,2015,Drug Quality Assurance,NAI,RemedyRepack Inc.,11/23/2015,11,23,2015,Written records are not made of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications .
953897,21 CFR 211.198(a),Complaint Handling Procedure,Indiana,Indianapolis,46211,United States,2015,Drug Quality Assurance,NAI,RemedyRepack Inc.,11/23/2015,11,23,2015,Procedures describing the handling of written and oral complaints related to drug products are not written or followed .
949342,21 CFR 211.28(a),Clothing appropriate for duties performed,California,Loma Linda,92350,United States,2015,Drug Quality Assurance,NAI,"Central Admixture Pharmacy Services, Inc.",11/20/2015,11,20,2015,"Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform."
949342,21 CFR 211.42(b),Product flow through building is inadequate,Minnesota,Rochester,55905,United States,2015,Drug Quality Assurance,VAI,"Central Admixture Pharmacy Services, Inc.",11/20/2015,11,20,2015,"The flow of components, drug product containers, closures, and drug products though the building is not designed to prevent contamination."
949342,21 CFR 211.42(c)(10)(iii),Air Supply,North Carolina,Durham,27713,United States,2015,Drug Quality Assurance,NAI,"Central Admixture Pharmacy Services, Inc.",11/20/2015,11,20,2015,Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
949342,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Pennsylvania,Morgantown,19543,United States,2015,Drug Quality Assurance,VAI,"Central Admixture Pharmacy Services, Inc.",11/20/2015,11,20,2015,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
949342,21 CFR 211.56(a),"Sanitation--buildings not clean, free of infestation",Washington,Spokane,99207,United States,2015,Drug Quality Assurance,VAI,"Central Admixture Pharmacy Services, Inc.",11/20/2015,11,20,2015,"Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition."
949342,21 CFR 211.84(d)(6),Microbiological Contamination Exam,New York,Watkins Glen,14891,United States,2015,Drug Quality Assurance,NAI,"Central Admixture Pharmacy Services, Inc.",11/20/2015,11,20,2015,"Each lot of a component, drug product container, and closure that is liable to microbiological contamination that is objectionable in view of its intended use is not subjected to microbiological tests before use."
949342,21 CFR 211.192,"Investigations of discrepancies, failures",Nevada,Las Vegas,89119,United States,2015,Drug Quality Assurance,OAI,"Central Admixture Pharmacy Services, Inc.",11/20/2015,11,20,2015,There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
948193,21 CFR 211.68(b),input/output verification,New York,New York,10016,United States,2015,Bioresearch Monitoring,NAI,Proficient Rx LP,10/22/2015,10,22,2015,Input to and output from the computer are not checked for accuracy.
948193,21 CFR 211.110(a),Control procedures to monitor and validate performance,New York,Cortland,13045,United States,2015,Drug Quality Assurance,VAI,Proficient Rx LP,10/22/2015,10,22,2015,Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
948193,21 CFR 211.180(e)(2),Items to cover on annual reviews,Missouri,Saint Louis,63128,United States,2015,Bioresearch Monitoring,VAI,Proficient Rx LP,10/22/2015,10,22,2015,"Written procedures are not established for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product."
948193,21 CFR 211.192,No written record of investigation,Georgia,Duluth,30097,United States,2015,Bioresearch Monitoring,NAI,Proficient Rx LP,10/22/2015,10,22,2015,Written records are not always made of investigations into unexplained discrepancies.
945306,21 CFR 211.42(a),"Buildings of Suitable Size, Construction, Location",Pennsylvania,Harrisburg,17102,United States,2015,Drug Quality Assurance,VAI,"Downing Labs, LLC",10/9/2015,10,9,2015,"Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations."
945306,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Tennessee,Smyrna,37167,United States,2015,Drug Quality Assurance,VAI,"Downing Labs, LLC",10/9/2015,10,9,2015,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
945306,21 CFR 211.42(c)(10)(v),Cleaning System,Ohio,Martins Ferry,43935,United States,2015,Drug Quality Assurance,NAI,"Downing Labs, LLC",10/9/2015,10,9,2015,Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
945306,21 CFR 211.100(a),Absence of Written Procedures,Alabama,Florence,35630,United States,2015,Drug Quality Assurance,NAI,"Downing Labs, LLC",10/9/2015,10,9,2015,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
945306,21 CFR 211.111,Establishment of time limitations,Alabama,Florence,35630,United States,2015,Drug Quality Assurance,NAI,"Downing Labs, LLC",10/9/2015,10,9,2015,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
945306,21 CFR 211.113(b),Validation lacking for sterile drug products,Massachusetts,Lexington,2421,United States,2015,Bioresearch Monitoring,VAI,"Downing Labs, LLC",10/9/2015,10,9,2015,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
945306,21 CFR 211.166(a),Lack of written stability program,New York,Deer Park,11729,United States,2015,Drug Quality Assurance,VAI,"Downing Labs, LLC",10/9/2015,10,9,2015,There is no written testing program designed to assess the stability characteristics of drug products.
945306,21 CFR 211.167(a),Sterility/pyrogen-free testing,Wisconsin,Monroe,53566,United States,2015,Drug Quality Assurance,VAI,"Downing Labs, LLC",10/9/2015,10,9,2015,Each batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements.
945306,21 CFR 211.192,"Investigations of discrepancies, failures",New Jersey,Princeton,8540,United States,2015,Drug Quality Assurance,NAI,"Downing Labs, LLC",10/9/2015,10,9,2015,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
941497,21 CFR 211.25(a),"Training , Education , Experience overall",New York,Syracuse,13202,United States,2015,Drug Quality Assurance,NAI,King Bio Inc.,9/4/2015,9,4,2015,"Employees engaged in the manufacture, processing, and holding of a drug product lack the training required to perform their assigned functions."
941497,21 CFR 211.42(d),Penicillin processing area not  kept separate,Maine,Lisbon Falls,4252,United States,2015,Drug Quality Assurance,NAI,King Bio Inc.,9/4/2015,9,4,2015,"The operations relating to the manufacture, processing, and packing of penicillin are not performed in facilities separate from those used for other drug products for human use."
941497,21 CFR 211.160(b),Scientifically sound laboratory controls,New Jersey,East Hanover,7936,United States,2015,Drug Quality Assurance,NAI,King Bio Inc.,9/4/2015,9,4,2015,"Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, in-process materials, and drug products conform to appropriate standards of identity, strength, quality and purity."
941497,21 CFR 211.166(a),Lack of written stability program,New Jersey,East Hanover,7936,United States,2015,Postmarket Surv. and Epidemiology,NAI,King Bio Inc.,9/4/2015,9,4,2015,There is no written testing program designed to assess the stability characteristics of drug products.
941497,21 CFR 211.166(a)(5),Testing of reconstituted drugs,New Jersey,Titusville,8560,United States,2015,Drug Quality Assurance,NAI,King Bio Inc.,9/4/2015,9,4,2015,The written stability program does not include testing of drug products for reconstitution after they are reconstituted.
941497,21 CFR 211.170(a),Active ingredient retained sample kept,Nebraska,Omaha,68127,United States,2015,Drug Quality Assurance,NAI,King Bio Inc.,9/4/2015,9,4,2015,A sample which is representative of each lot in each shipment of each active ingredient is not retained.
941497,21 CFR 211.176,Failing to test for penicillin cross-contamination,Virginia,Chesapeake,23323,United States,2015,Drug Quality Assurance,NAI,King Bio Inc.,9/4/2015,9,4,2015,"Non-penicillin drug products were not tested for the presence of penicillin, when a reasonable possibility existed that a non-penicillin drug product has been exposed to a cross-contamination with penicillin."
941497,21 CFR 211.182,Personnel  dating/signing equipment log,New York,Saranac Lake,12983,United States,2015,Drug Quality Assurance,NAI,King Bio Inc.,9/4/2015,9,4,2015,The persons double-checking the cleaning and maintenance are not dating and signing or initialing the equipment cleaning and use log.
941434,21 CFR 314.80(c)(1)(i),Late submission of 15-day report,Indiana,Fort Wayne,46818,United States,2015,Drug Quality Assurance,NAI,"Sun Pharmaceutical Industries, Inc.",8/27/2015,8,27,2015,Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
941434,21 CFR 314.80(c)(1)(ii),Submission of report follow-up,New York,Aquebogue,11931,United States,2015,Drug Quality Assurance,VAI,"Sun Pharmaceutical Industries, Inc.",8/27/2015,8,27,2015,Follow-up reports were not submitted within 15 calendar days of receipt of new information concerning post marketing 15-day reports.
946884,21 CFR 314.80(j),Failure to maintain records,Virginia,Richmond,23294,United States,2015,Bioresearch Monitoring,NAI,Pfizer Inc.,8/26/2015,8,26,2015,"Records relating to all adverse drug experiences known to you, including raw data and any correspondence, have not been maintained for the required ten year period."
943389,21 CFR 211.150(b),Distribution Recall System,Kansas,Mcpherson,67460,United States,2015,Drug Quality Assurance,VAI,"Lincare, Inc.",8/21/2015,8,21,2015,The distribution system is deficient in that each lot of drug product cannot be readily determined to facilitate its recall if necessary.
938765,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Oregon,Portland,97239,United States,2015,Drug Quality Assurance,VAI,"Lincare, Inc.",8/20/2015,8,20,2015,The responsibilities and procedures applicable to the quality control unit are not fully followed.
937344,21 CFR 211.160(b)(4),Establishment of calibration procedures,Massachusetts,Boston,2215,United States,2015,Bioresearch Monitoring,NAI,Novartis Pharmaceuticals Corporation,7/17/2015,7,17,2015,"Procedures describing the calibration of instruments, apparatus, gauges and recording devices are deficiently written or followed."
937344,21 CFR 211.166(a)(4),Testing in same container - closure system,California,Irvine,92618,United States,2015,Drug Quality Assurance,VAI,Novartis Pharmaceuticals Corporation,7/17/2015,7,17,2015,The written stability program does not assure testing of the drug product in the same container-closure system as that in which the drug product is marketed.
937344,21 CFR 211.170(b),"Reserve samples identified, representative, stored",New Jersey,Freehold,7728,United States,2015,Bioresearch Monitoring,NAI,Novartis Pharmaceuticals Corporation,7/17/2015,7,17,2015,Reserve drug product samples are not representative of each lot or batch of drug product.
934347,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Ohio,Cleveland,44106,United States,2015,Bioresearch Monitoring,VAI,"Sun Pharmaceutical Industries, Inc.",7/15/2015,7,15,2015,The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
934347,21 CFR 211.160(b)(4),Establishment of calibration procedures,Texas,Stafford,77477,United States,2015,Drug Quality Assurance,NAI,"Sun Pharmaceutical Industries, Inc.",7/15/2015,7,15,2015,"Procedures describing the calibration of instruments, apparatus, gauges and recording devices are deficiently written or followed."
934347,21 CFR 314.80(b),Failure to develop written procedures,Georgia,Atlanta,30312,United States,2015,Bioresearch Monitoring,NAI,"Sun Pharmaceutical Industries, Inc.",7/15/2015,7,15,2015,"Written procedures have not been developed for the surveillance, receipt, evaluation, and reporting to FDA of post marketing adverse drug experiences."
934846,21 CFR 211.100(a),Absence of Written Procedures,Louisiana,Shreveport,71101,United States,2015,Bioresearch Monitoring,NAI,"Noven Pharmaceuticals, Inc.",7/10/2015,7,10,2015,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
934846,21 CFR 211.111,Establishment of time limitations,New York,Cedarhurst,11516,United States,2015,Over-the-Counter Drug Evaluation,NAI,"Noven Pharmaceuticals, Inc.",7/10/2015,7,10,2015,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
934241,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Nevada,Las Vegas,89113,United States,2015,Drug Quality Assurance,OAI,"Hartley Medical Center Pharmacy, Incorporated",7/8/2015,7,8,2015,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
934241,21 CFR 211.113(b),Validation lacking for sterile drug products,Arkansas,Hot Springs,71913,United States,2015,Drug Quality Assurance,VAI,"Hartley Medical Center Pharmacy, Incorporated",7/8/2015,7,8,2015,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
932630,21 CFR 211.192,Quality control unit review of records,Missouri,Kansas City,64137,United States,2015,Drug Quality Assurance,NAI,"Lincare, Inc.",6/11/2015,6,11,2015,"Drug product production and control records, are not reviewed by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed."
932525,21 CFR 211.22(a),"Authority lacking to review records, investigate errors",New Jersey,Washington,7882,United States,2015,Drug Quality Assurance,VAI,"Par Pharmaceutical, Inc.",6/4/2015,6,4,2015,The quality control unit lacks authority to fully investigate errors that have occurred.
932525,21 CFR 211.192,"Investigations of discrepancies, failures",Louisiana,Baton Rouge,70808,United States,2015,Drug Quality Assurance,VAI,"Par Pharmaceutical, Inc.",6/4/2015,6,4,2015,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
928826,21 CFR 211.100(a),Absence of Written Procedures,Minnesota,Minneapolis,55454,United States,2015,Bioresearch Monitoring,NAI,"VistaPharm, Inc.",5/28/2015,5,28,2015,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
928826,21 CFR 211.100(a),"Changes to Procedures Not Reviewed, Approved",New Jersey,Paterson,7524,United States,2015,Drug Quality Assurance,VAI,"VistaPharm, Inc.",5/28/2015,5,28,2015,"Changes to written procedures are not drafted, reviewed and approved by the appropriate organizational unit."
928826,21 CFR 211.166(b),Accelerated stability studies,Washington,Richland,99352,United States,2015,Bioresearch Monitoring,VAI,"VistaPharm, Inc.",5/28/2015,5,28,2015,"Accelerated stability studies, combined with basic stability information, used to support tentative expiration dates are not supported with ongoing full shelf life studies."
928826,21 CFR 211.186(b)(9),"Complete instructions, procedures, specifications et. al.",Ohio,Cadiz,43907,United States,2015,Bioresearch Monitoring,VAI,"VistaPharm, Inc.",5/28/2015,5,28,2015,"Master production and control records lack complete manufacturing and control instructions, sampling and testing procedures, specifications, special notations, and precautions to be followed."
928826,21 CFR 211.192,"Investigations of discrepancies, failures",Florida,SARASOTA,34234,United States,2015,Drug Quality Assurance,NAI,"VistaPharm, Inc.",5/28/2015,5,28,2015,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
928826,21 CFR 211.198(a),Procedures to be written and followed,New Jersey,Raritan,8869,United States,2015,Drug Quality Assurance,NAI,"VistaPharm, Inc.",5/28/2015,5,28,2015,Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.
928826,21 CFR 314.81(b)(1)(ii),Failure to meet specifications,Delaware,Wilmington,19804,United States,2015,Drug Quality Assurance,NAI,"VistaPharm, Inc.",5/28/2015,5,28,2015,An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning a failure of one or more distributed batches of a drug to meet the specifications established for it in the application.
927328,21 CFR 211.28(a),Clothing appropriate for duties performed,Arkansas,Atkins,72823,United States,2015,Unapproved and Misbranded Drugs,OAI,Liberty Drug & Surgical,5/22/2015,5,22,2015,"Clothing of personnel engaged in the manufacturing, processing, packing, and holding of drug products is not appropriate for the duties they perform."
927328,21 CFR 211.42(a),"Buildings of Suitable Size, Construction, Location",Puerto Rico,Guayama,784,United States,2015,Drug Quality Assurance,VAI,Liberty Drug & Surgical,5/22/2015,5,22,2015,"Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable size, construction, and location to facilitate cleaning, maintenance, and proper operations."
927328,21 CFR 211.42(b),Product flow through building is inadequate,Oregon,Salem,97301,United States,2015,Bioresearch Monitoring,VAI,Liberty Drug & Surgical,5/22/2015,5,22,2015,"The flow of components, drug product containers, closures, in-process materials, and drug products though the building is not designed to prevent contamination."
927328,21 CFR 211.100(b),SOPs not followed / documented,New York,New York,10065,United States,2015,Bioresearch Monitoring,NAI,Liberty Drug & Surgical,5/22/2015,5,22,2015,Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.
927328,21 CFR 211.113(b),Procedures for sterile drug products,California,Thousand Oaks,91320,United States,2015,Bioresearch Monitoring,NAI,Liberty Drug & Surgical,5/22/2015,5,22,2015,"Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed."
927328,21 CFR 211.166(a)(3),Valid stability test methods,Wisconsin,Kenosha,53144,United States,2015,Drug Quality Assurance,NAI,Liberty Drug & Surgical,5/22/2015,5,22,2015,"The written stability program for drug products does not include reliable, meaningful, and specific test methods."
928801,21 CFR 211.28(a),Clothing appropriate for duties performed,Florida,Hollywood,33024,United States,2015,Bioresearch Monitoring,VAI,The Compounding Pharmacy of America,5/21/2015,5,21,2015,"Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform."
928801,21 CFR 211.42(c)(10)(iii),Air Supply,New Jersey,Carlstadt,7072,United States,2015,Drug Quality Assurance,OAI,The Compounding Pharmacy of America,5/21/2015,5,21,2015,Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
928801,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,New Jersey,Carlstadt,7072,United States,2015,Unapproved and Misbranded Drugs,OAI,The Compounding Pharmacy of America,5/21/2015,5,21,2015,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
928801,21 CFR 211.42(c)(10)(v),Cleaning System,Illinois,Vernon Hills,60061,United States,2015,Drug Quality Assurance,VAI,The Compounding Pharmacy of America,5/21/2015,5,21,2015,Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
928801,21 CFR 211.68(a),Calibration/Inspection/Checking not done,New York,New Paltz,12561,United States,2015,Drug Quality Assurance,VAI,The Compounding Pharmacy of America,5/21/2015,5,21,2015,Routine calibration of  equipment is not performed according to a written program designed to assure proper performance.
928801,21 CFR 211.84(d)(2),Reports of Analysis (Components),Ohio,Cincinnati,45202,United States,2015,Bioresearch Monitoring,NAI,The Compounding Pharmacy of America,5/21/2015,5,21,2015,"Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals."
928801,21 CFR 211.167(a),Sterility/pyrogen-free testing,Tennessee,Memphis,38104,United States,2015,Bioresearch Monitoring,VAI,The Compounding Pharmacy of America,5/21/2015,5,21,2015,Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
927965,21 CFR 314.80(c)(1)(i),Late submission of 15-day report,Wisconsin,Verona,53593,United States,2015,Drug Quality Assurance,VAI,Apotex Inc.,5/11/2015,5,11,2015,Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
927965,21 CFR 314.80(c)(2),Late submission of quarterly safety reports,New Jersey,Lakewood,8701,United States,2015,Drug Quality Assurance,NAI,Apotex Inc.,5/11/2015,5,11,2015,Not all quarterly periodic adverse drug experience reports have been submitted within 30 days of the close of the quarter.
925338,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Georgia,Atlanta,30336,United States,2015,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,5/1/2015,5,1,2015,The responsibilities and procedures applicable to the quality control unit are not fully followed.
925338,21 CFR 211.84(a),Components withheld from use pending release,Texas,Houston,77030,United States,2015,Bioresearch Monitoring,VAI,Baxter Healthcare Corporation,5/1/2015,5,1,2015,"Each lot of components and closures is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit."
925338,21 CFR 211.94(b),Protection from external factors,New Jersey,Mahwah,7430,United States,2015,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,5/1/2015,5,1,2015,Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.
925338,21 CFR 211.110(a),Control procedures to monitor and validate performance,Colorado,Colorado Springs,80907,United States,2015,Bioresearch Monitoring,OAI,Baxter Healthcare Corporation,5/1/2015,5,1,2015,Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
925338,21 CFR 211.192,"Investigations of discrepancies, failures",Colorado,Colorado Springs,80907,United States,2015,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,5/1/2015,5,1,2015,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
933105,21 CFR 211.100(a),Absence of Written Procedures,California,Newport Beach,92660,United States,2015,Drug Quality Assurance,OAI,Mylan Pharmaceuticals Inc.,4/24/2015,4,24,2015,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
918472,21 CFR 211.58,Buildings not maintained in good state of repair,New York,S New Berlin,13843,United States,2014,Drug Quality Assurance,NAI,Natural Health Supply,3/19/2015,3,19,2015,Buildings used in the manufacturing of a drug product are not maintained in a good state of repair.
918472,21 CFR 211.100(a),Approval and review of procedures,North Carolina,Greensboro,27406,United States,2014,Drug Quality Assurance,NAI,Natural Health Supply,3/19/2015,3,19,2015,Written procedures are not reviewed and approved by the quality control unit.
918472,21 CFR 211.160(b)(4),"Calibration - at intervals, written program, remedial action",California,Moorpark,93021,United States,2014,Drug Quality Assurance,OAI,Natural Health Supply,3/19/2015,3,19,2015,The calibration of apparatus is not done at suitable intervals .
918472,21 CFR 211.165(a),Testing and release for distribution,Tennessee,Memphis,38134,United States,2014,Drug Quality Assurance,NAI,Natural Health Supply,3/19/2015,3,19,2015,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
918472,21 CFR 211.166(c)(1),"Homeopathic drugs, assessment of stability",Florida,Mims,32754,United States,2014,Drug Quality Assurance,NAI,Natural Health Supply,3/19/2015,3,19,2015,There is no written assessment of stability of homeopathic drug products based at least on testing or examination of the drug product for compatibility of the ingredients and marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use.
918472,21 CFR 211.198(b)(1),Complaint Record required information,Texas,Waco,76712,United States,2014,Drug Quality Assurance,NAI,Natural Health Supply,3/19/2015,3,19,2015,"Complaint records are deficient in that they do not include the known name and strength of the drug product, name of complainant, and nature of complaint."
913527,21 CFR 211.63,"Equipment Design, Size and Location",New Jersey,Somerset,8873,United States,2014,Drug Quality Assurance,NAI,Medline Industries Inc,3/11/2015,3,11,2015,"Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use."
913527,21 CFR 211.68(b),input/output verification,Wisconsin,Madison,53714,United States,2014,Drug Quality Assurance,NAI,Medline Industries Inc,3/11/2015,3,11,2015,Input to and output from the computer are not checked for accuracy.
913527,21 CFR 211.84(a),Components withheld from use pending release,Louisiana,Hahnville,70057,United States,2014,Drug Quality Assurance,NAI,Medline Industries Inc,3/11/2015,3,11,2015,"Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit."
913527,21 CFR 211.84(d)(2),Reports of Analysis (Components),North Carolina,Brevard,28712,United States,2014,Drug Quality Assurance,NAI,Medline Industries Inc,3/11/2015,3,11,2015,"Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals."
913527,21 CFR 211.84(e),Rejecting  When Specifications Not Met,North Carolina,Brevard,28712,United States,2014,Over-the-Counter Drug Evaluation,VAI,Medline Industries Inc,3/11/2015,3,11,2015,"Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity."
913527,21 CFR 211.160(b),Scientifically sound laboratory controls,Massachusetts,Adams,1220,United States,2014,Drug Quality Assurance,VAI,Medline Industries Inc,3/11/2015,3,11,2015,"Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, and drug products conform to appropriate standards of identity, strength, quality and purity."
913527,21 CFR 211.165(f),Failing drug products not rejected,South Carolina,Charleston,29407,United States,2014,Drug Quality Assurance,VAI,Medline Industries Inc,3/11/2015,3,11,2015,Drug products failing to meet established specifications are not rejected.
913527,21 CFR 211.180(e)(2),Items to cover on annual reviews,Puerto Rico,Humacao,791,United States,2014,Drug Quality Assurance,NAI,Medline Industries Inc,3/11/2015,3,11,2015,Written procedures are not established and followed for evaluations done at least annually and including provisions for a review of investigations conducted for each drug product.
913527,21 CFR 211.192,"Investigations of discrepancies, failures",Ohio,Franklin,45005,United States,2014,Drug Quality Assurance,NAI,Medline Industries Inc,3/11/2015,3,11,2015,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
913527,21 CFR 211.194(a)(2),Suitability of testing methods verified,Ohio,Rittman,44270,United States,2014,Drug Quality Assurance,NAI,Medline Industries Inc,3/11/2015,3,11,2015,The suitability of all testing methods is not verified under actual conditions of use.
919303,21 CFR 211.84(d)(6),Objectionable microbiological contamination,Arizona,Scottsdale,85250,United States,2014,Postmarket Surv. and Epidemiology,NAI,"Health Innovations Pharmacy, Inc",2/27/2015,2,27,2015,Each lot of a component liable to objectionable microbiological contamination is deficiently subjected to microbiological tests before use.
919303,21 CFR 211.111,Establishment of time limitations,California,Hayward,94544,United States,2014,Drug Quality Assurance,VAI,"Health Innovations Pharmacy, Inc",2/27/2015,2,27,2015,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
919303,21 CFR 211.113(b),Validation lacking for sterile drug products,Kentucky,Lexington,40509,United States,2014,Drug Quality Assurance,NAI,"Health Innovations Pharmacy, Inc",2/27/2015,2,27,2015,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
919303,21 CFR 211.165(a),Testing and release for distribution,Tennessee,Jackson,38301,United States,2014,Bioresearch Monitoring,VAI,"Health Innovations Pharmacy, Inc",2/27/2015,2,27,2015,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the prior to release.
919303,21 CFR 211.165(b),Microbiological testing,Kansas,Wichita,67214,United States,2014,Bioresearch Monitoring,VAI,"Health Innovations Pharmacy, Inc",2/27/2015,2,27,2015,Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
919303,21 CFR 211.166(a),Lack of written stability program,Texas,San Antonio,78238,United States,2014,Drug Quality Assurance,VAI,"Health Innovations Pharmacy, Inc",2/27/2015,2,27,2015,There is no written testing program designed to assess the stability characteristics of drug products.
919303,21 CFR 211.167(a),Sterility/pyrogen-free testing,South Carolina,Columbia,29210,United States,2014,Drug Quality Assurance,NAI,"Health Innovations Pharmacy, Inc",2/27/2015,2,27,2015,Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
918332,21 CFR 211.84(d)(3),Testing Containers & Closures Conformity with Specs,New York,Farmingdale,11735,United States,2014,Drug Quality Assurance,VAI,Lloyd Inc. of Iowa,2/20/2015,2,20,2015,Containers and closures are not tested for conformance with all appropriate written procedures.
918332,21 CFR 211.103,Actual vs. theoretical yields not determined,Florida,South Miami,33143,United States,2014,Bioresearch Monitoring,NAI,Lloyd Inc. of Iowa,2/20/2015,2,20,2015,Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of manufacturing of the drug product.
918332,21 CFR 211.110(a),Control procedures to monitor and validate performance,Connecticut,Ridgefield,6877,United States,2014,Bioresearch Monitoring,NAI,Lloyd Inc. of Iowa,2/20/2015,2,20,2015,Control procedures are not established which of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
918332,21 CFR 211.160(b)(2),"In-process samples representative, identified properly",Ohio,Cleveland,44113,United States,2014,Drug Quality Assurance,NAI,Lloyd Inc. of Iowa,2/20/2015,2,20,2015,Samples taken of in-process materials for determination of conformance to specifications are not representative.
918332,21 CFR 211.160(b)(4),"Calibration - at intervals, written program, remedial action",Massachusetts,Westborough,1581,United States,2014,Drug Quality Assurance,NAI,Lloyd Inc. of Iowa,2/20/2015,2,20,2015,"The calibration of instruments, gauges, and recording devices is not done at suitable intervals in accordance with an established written program."
918332,21 CFR 211.165(e),Test methods,Florida,Miami,33137,United States,2014,Bioresearch Monitoring,NAI,Lloyd Inc. of Iowa,2/20/2015,2,20,2015,"The sensitivity, specificity, and reproducibility of test methods have not been established and documented."
918332,21 CFR 211.166(a)(3),Valid stability test methods,New York,Hicksville,11801,United States,2014,Drug Quality Assurance,NAI,Lloyd Inc. of Iowa,2/20/2015,2,20,2015,"The written stability program for drug products does not include reliable, meaningful, and specific test methods."
915252,21 CFR 211.100(a),Absence of Written Procedures,New Jersey,Edison,8837,United States,2014,Drug Quality Assurance,OAI,Product Quest Manufacturing LLC,2/18/2015,2,18,2015,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
915252,21 CFR 211.115(a),Reprocessing procedures not written or followed,Oklahoma,Newcastle,73065,United States,2014,Drug Quality Assurance,NAI,Product Quest Manufacturing LLC,2/18/2015,2,18,2015,"Procedures prescribing a system for reprocessing batches to insure that the reprocessed batches will conform with all established standards, specifications, and characteristics are not followed."
915252,21 CFR 211.180(e)(2),Review of problem drugs,West Virginia,Milton,25541,United States,2014,Drug Quality Assurance,VAI,Product Quest Manufacturing LLC,2/18/2015,2,18,2015,"The procedures for the annual quality standards record evaluation are deficient in that they do not address a review of complaint, recall, returned drug product, salvaged drug product, and investigation records for each drug product."
915252,21 CFR 211.192,"Investigations of discrepancies, failures",Pennsylvania,Fort Washington,19034,United States,2014,Bioresearch Monitoring,NAI,Product Quest Manufacturing LLC,2/18/2015,2,18,2015,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
914112,21 CFR 211.28(a),Clothing appropriate for duties performed,Indiana,Indianapolis,46226,United States,2014,Drug Quality Assurance,OAI,"Central Admixture Pharmacy Services, Inc.",2/11/2015,2,11,2015,"Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform."
914112,21 CFR 211.113(b),Procedures for sterile drug products,Maryland,Salisbury,21801,United States,2014,Postmarket Surv. and Epidemiology,NAI,"Central Admixture Pharmacy Services, Inc.",2/11/2015,2,11,2015,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and written.
914112,21 CFR 211.113(b),Validation lacking for sterile drug products,California,Concord,94520,United States,2014,Drug Quality Assurance,VAI,"Central Admixture Pharmacy Services, Inc.",2/11/2015,2,11,2015,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
914112,21 CFR 211.188(a),Accurate reproduction included,Florida,Miami,33136,United States,2014,Bioresearch Monitoring,OAI,"Central Admixture Pharmacy Services, Inc.",2/11/2015,2,11,2015,"Batch production and control records for each batch of drug product produced do not include an accurate reproduction of the appropriate master production or control record which was checked for accuracy, dated and signed."
914112,21 CFR 211.192,"Investigations of discrepancies, failures",New Jersey,Jackson,8527,United States,2014,Drug Quality Assurance,NAI,"Central Admixture Pharmacy Services, Inc.",2/11/2015,2,11,2015,There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
912250,21 CFR 211.68(b),Computer control of master formula records,Colorado,Englewood,80112,United States,2014,Drug Quality Assurance,NAI,Boiron,1/15/2015,1,15,2015,Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
912250,21 CFR 211.84(a),Components withheld from use pending release,Rhode Island,West Warwick,2893,United States,2014,Drug Quality Assurance,VAI,Boiron,1/15/2015,1,15,2015,"Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit."
912250,21 CFR 211.100(a),Absence of Written Procedures,Tennessee,Germantown,38138,United States,2014,Bioresearch Monitoring,NAI,Boiron,1/15/2015,1,15,2015,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
912250,21 CFR 211.101(d),Component addition checked by 2nd person,Pennsylvania,Allentown,18106,United States,2014,Drug Quality Assurance,OAI,Boiron,1/15/2015,1,15,2015,Each component is not added to a batch by one person and verified by a second person.
912250,21 CFR 211.111,Establishment of time limitations,Tennessee,Bristol,37620,United States,2014,Drug Quality Assurance,VAI,Boiron,1/15/2015,1,15,2015,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
912250,21 CFR 211.160(b),Scientifically sound laboratory controls,Washington,Bellevue,98007,United States,2014,Bioresearch Monitoring,VAI,Boiron,1/15/2015,1,15,2015,"Laboratory controls do not include the establishment of scientifically sound and appropriate designed to assure that conform to appropriate standards of identity, strength, quality and purity."
912250,21 CFR 211.186(b)(9),Manufacturing Instructions and Specifications,Florida,Tampa,33625,United States,2014,Drug Quality Assurance,NAI,Boiron,1/15/2015,1,15,2015,"The master production and control records are deficient in that they do not include complete control, instructions, and procedures."
912250,21 CFR 211.192,Quality control unit review of records,Texas,Houston,77037,United States,2014,Bioresearch Monitoring,VAI,Boiron,1/15/2015,1,15,2015,"Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed."
912250,21 CFR 211.192,Written record of investigation incomplete,Pennsylvania,Philadelphia,19154,United States,2014,Drug Quality Assurance,NAI,Boiron,1/15/2015,1,15,2015,Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
907020,21 CFR 211.165(e),Test methods,New Jersey,Pennington,8534,United States,2014,Postmarket Surv. and Epidemiology,NAI,Watson Laboratories Inc,12/8/2014,12,8,2014,The accuracy and reproducibility of test methods have not been established.
907020,21 CFR 211.192,Written record of investigation incomplete,Ohio,Oakwood Village,44146,United States,2014,Drug Quality Assurance,NAI,Watson Laboratories Inc,12/8/2014,12,8,2014,Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
901775,21 CFR 211.42(a),"Buildings of Suitable Size, Construction, Location",Virginia,Roanoke,24018,United States,2014,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",10/24/2014,10,24,2014,"Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations."
901775,21 CFR 211.84(b),Representative Samples Criteria,Pennsylvania,Aston,19014,United States,2014,Unapproved and Misbranded Drugs,OAI,"Fresenius Kabi USA, LLC",10/24/2014,10,24,2014,The number of containers to be sampled is not based upon appropriate criteria.
895649,21 CFR 211.160(a),Following/documenting laboratory controls,New Jersey,Princeton,8540,United States,2014,Bioresearch Monitoring,VAI,L. Perrigo Company,9/16/2014,9,16,2014,Established test procedures are not documented at the time of performance.
895649,21 CFR 211.165(e),Test methods,Ohio,Lima,45804,United States,2014,Drug Quality Assurance,NAI,L. Perrigo Company,9/16/2014,9,16,2014,The reproducibility of test methods have not been established and documented.
895238,21 CFR 211.160(b)(1),Incoming lots - conformance to written specs-,California,South San Francisco,94080,United States,2014,Postmarket Surv. and Epidemiology,VAI,Merck Sharp & Dohme Corp.,9/12/2014,9,12,2014,"Laboratory controls do not include determination of conformance to appropriate written specifications for the acceptance of each lot within each shipment of components and in-process materials used in the manufacture, processing, packing, or holding of drug products."
895756,21 CFR 211.198(a),Complaint Handling Procedure,Arizona,Chandler,85224,United States,2014,Drug Quality Assurance,NAI,Cadila Healthcare Limited,9/5/2014,9,5,2014,Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.
885413,21 CFR 211.42(c),Defined areas of adequate size for operations,North Carolina,Raleigh,27607,United States,2014,Bioresearch Monitoring,NAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,The control systems necessary to prevent contamination or mix-ups are deficient.
885413,21 CFR 211.46(b),Equipment for Environmental Control,North Carolina,Asheville,28803,United States,2014,Drug Quality Assurance,OAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,"Equipment for adequate control over micro-organisms is not provided when appropriate for the manufacture, processing, packing or holding of a drug product."
885413,21 CFR 211.65(a),Equipment construction - reactive surfaces,California,Los Angeles,90013,United States,2014,Bioresearch Monitoring,VAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,"Equipment surfaces that contact components and in-process materials are reactive, additive or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements."
885413,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Florida,Tamarac,33321,United States,2014,Unapproved and Misbranded Drugs,VAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,"Equipment and utensils are not cleaned, maintained, and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
885413,21 CFR 211.80(b),Handling and Storage to Prevent Contamination,Florida,Palm Springs,33406,United States,2014,Drug Quality Assurance,VAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,There was a failure to handle and store drug product containers at all times in a manner to prevent contamination.
885413,21 CFR 211.84(d)(2),Reports of Analysis (Components),Florida,Palm Springs,33406,United States,2014,Unapproved and Misbranded Drugs,NAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,"Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals."
885413,21 CFR 211.94(c),"Containers & Closures Clean, Sterilized, Pyrogen-free",California,Los Angeles,90057,United States,2014,Bioresearch Monitoring,VAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
885413,21 CFR 211.111,Establishment of time limitations,New Jersey,New Brunswick,8901,United States,2014,Drug Quality Assurance,NAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
885413,21 CFR 211.166(a),Lack of written stability program,California,La Verne,91750,United States,2014,Bioresearch Monitoring,NAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,There is no written testing program designed to assess the stability characteristics of drug products.
885413,21 CFR 211.167(a),Sterility/pyrogen-free testing,California,City Of Industry,91746,United States,2014,Drug Quality Assurance,NAI,"Martin Avenue Pharmacy, Inc.",7/21/2014,7,21,2014,Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
887817,21 CFR 211.22(b),Adequate lab facilities not available,Missouri,Fenton,63026,United States,2014,Drug Quality Assurance,NAI,"Downing Labs, LLC",7/16/2014,7,16,2014,Adequate lab facilities for testing and approval or rejection of drug products are not available to the quality control unit.
887817,21 CFR 211.22(c),Approve or reject procedures or specs,Michigan,Grand Haven,49417,United States,2014,Drug Quality Assurance,VAI,"Downing Labs, LLC",7/16/2014,7,16,2014,The quality control unit lacks responsibility to approve all procedures or specifications impacting on the quality and purity of drug products.
887817,21 CFR 211.28(a),Clothing appropriate for duties performed,Minnesota,Saint Paul,55104,United States,2014,Drug Quality Assurance,NAI,"Downing Labs, LLC",7/16/2014,7,16,2014,Clothing of personnel engaged in the manufacturing of drug products is not appropriate for the duties they perform.
887817,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,New Jersey,Rahway,7065,United States,2014,Drug Quality Assurance,NAI,"Downing Labs, LLC",7/16/2014,7,16,2014,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
887817,21 CFR 211.42(c)(10)(v),Cleaning System,New Jersey,Rockaway,7866,United States,2014,Drug Quality Assurance,NAI,"Downing Labs, LLC",7/16/2014,7,16,2014,Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
887817,21 CFR 211.42(c)(10)(vi),Equipment to control conditions,Minnesota,Saint Paul,55120,United States,2014,Drug Quality Assurance,VAI,"Downing Labs, LLC",7/16/2014,7,16,2014,Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
887817,21 CFR 211.63,"Equipment Design, Size and Location",Pennsylvania,Donora,15033,United States,2014,Drug Quality Assurance,NAI,"Downing Labs, LLC",7/16/2014,7,16,2014,"Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use."
887817,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Florida,Largo,33773,United States,2014,Drug Quality Assurance,NAI,"Downing Labs, LLC",7/16/2014,7,16,2014,"Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product."
887817,21 CFR 211.113(b),Procedures for sterile drug products,Nevada,Las Vegas,89106,United States,2014,Drug Quality Assurance,VAI,"Downing Labs, LLC",7/16/2014,7,16,2014,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
887817,21 CFR 211.166(a),Lack of written stability program,Nevada,Las Vegas,89118,United States,2014,Drug Quality Assurance,VAI,"Downing Labs, LLC",7/16/2014,7,16,2014,There is no written testing program designed to assess the stability characteristics of drug products.
887817,21 CFR 211.167(a),Sterility/pyrogen-free testing,New Jersey,Bridgewater,8807,United States,2014,Drug Quality Assurance,NAI,"Downing Labs, LLC",7/16/2014,7,16,2014,Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
887817,21 CFR 211.192,"Investigations of discrepancies, failures",New Jersey,Phillipsburg,8865,United States,2014,Drug Quality Assurance,NAI,"Downing Labs, LLC",7/16/2014,7,16,2014,There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
884768,21 CFR 211.22(a),"Approve or reject components, products",Idaho,Boise,83705,United States,2014,Drug Quality Assurance,NAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,The quality control unit lacks the responsibility and authority to approve and reject all drug products.
884768,21 CFR 211.28(a),Clothing appropriate for duties performed,New York,Amityville,11701,United States,2014,Drug Quality Assurance,VAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.
884768,21 CFR 211.42(c)(10)(iii),Air Supply,New York,Amityville,11701,United States,2014,Postmarket Surv. and Epidemiology,VAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
884768,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Louisiana,Hammond,70403,United States,2014,Bioresearch Monitoring,NAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
884768,21 CFR 211.84(d)(2),Establish reliability of supplier's C of A,Massachusetts,Hingham,2043,United States,2014,Drug Quality Assurance,VAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
884768,21 CFR 211.100(a),Absence of Written Procedures,New York,Amityville,11701,United States,2014,Drug Quality Assurance,VAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
884768,21 CFR 211.113(b),Procedures for sterile drug products,New York,Amityville,11701,United States,2014,Postmarket Surv. and Epidemiology,VAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,"Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed."
884768,21 CFR 211.165(b),Microbiological testing,Rhode Island,Cumberland,2864,United States,2014,Drug Quality Assurance,VAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
884768,21 CFR 211.166(a),Lack of written stability program,Minnesota,Minneapolis,55412,United States,2014,Drug Quality Assurance,NAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,There is no written testing program designed to assess the stability characteristics of drug products.
884768,21 CFR 211.166(a)(5),Testing of reconstituted drugs,California,La Mesa,91942,United States,2014,Bioresearch Monitoring,VAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,The written stability program does not include testing of drug products for reconstitution after they are reconstituted.
884768,21 CFR 211.188,"Prepared for each batch, include complete information",Maine,Auburn,4210,United States,2014,Bioresearch Monitoring,NAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,Batch production and control records do not include complete information relating to the production and control of each batch.
884768,21 CFR 211.198(a),Complaint Handling Procedure,New Jersey,Edison,8817,United States,2014,Drug Quality Assurance,NAI,Wells Pharmacy Network LLC,6/19/2014,6,19,2014,Procedures describing the handling of written and oral complaints related to drug products are not written or followed.
883358,21 CFR 211.56(a),"Sanitation--buildings not clean, free of infestation",Georgia,Atlanta,30338,United States,2014,Bioresearch Monitoring,NAI,"Central Admixture Pharmacy Services, Inc.",6/11/2014,6,11,2014,"Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition."
883358,21 CFR 211.84(a),Components withheld from use pending release,Texas,Houston,77030,United States,2014,Bioresearch Monitoring,VAI,"Central Admixture Pharmacy Services, Inc.",6/11/2014,6,11,2014,"Each lot of is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit."
883358,21 CFR 211.113(b),Procedures for sterile drug products,New Jersey,Rahway,7065,United States,2014,Bioresearch Monitoring,VAI,"Central Admixture Pharmacy Services, Inc.",6/11/2014,6,11,2014,"Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed."
880292,21 CFR 314.80(c)(1)(i),Late submission of 15-day report,California,Anaheim,92806,United States,2013,Drug Quality Assurance,VAI,Lupin Pharmaceuticals Inc.,5/23/2014,5,23,2014,Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
875552,21 CFR 211.160(b),Scientifically sound laboratory controls,New Jersey,Ledgewood,7852,United States,2013,Drug Quality Assurance,OAI,Watson Laboratories Inc,4/21/2014,4,21,2014,"Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity."
875552,21 CFR 211.165(e),Test methods,New York,Cortland,13045,United States,2013,Drug Quality Assurance,NAI,Watson Laboratories Inc,4/21/2014,4,21,2014,"The accuracy, sensitivity, specificity, and reproducibility of test methods have not been established."
872676,21 CFR 211.100(b),SOPs not followed / documented,New Jersey,Kenilworth,7033,United States,2013,Drug Quality Assurance,NAI,"Pharmakon Pharmaceuticals, Inc.",4/8/2014,4,8,2014,Written production and process control procedures are not followed in the execution of production and process control functions.
872676,21 CFR 211.130(d),Examination of packaging and labeling,Pennsylvania,Philadelphia,19136,United States,2013,Drug Quality Assurance,VAI,"Pharmakon Pharmaceuticals, Inc.",4/8/2014,4,8,2014,Examination of packaging and labeling materials for suitability and correctness before packaging operations is not performed and not documented in the batch production records.
872676,21 CFR 211.134(c),Examinations documented,Pennsylvania,Philadelphia,19136,United States,2013,Unapproved and Misbranded Drugs,NAI,"Pharmakon Pharmaceuticals, Inc.",4/8/2014,4,8,2014,The results of the examination of the packaged and labeled products were not documented in the batch production or control records.
872676,21 CFR 211.186(a),Signature and checking of records -- 2 persons,Maryland,Baltimore,21201,United States,2013,Bioresearch Monitoring,VAI,"Pharmakon Pharmaceuticals, Inc.",4/8/2014,4,8,2014,"The master production and control records for each batch size of drug product are not prepared, dated, and signed by one person with a full handwritten signature and independently checked, dated, and signed by a second person."
872676,21 CFR 211.192,"Investigations of discrepancies, failures",Ohio,Cincinnati,45219,United States,2013,Bioresearch Monitoring,NAI,"Pharmakon Pharmaceuticals, Inc.",4/8/2014,4,8,2014,There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
877947,21 CFR 211.42(c)(10)(v),Cleaning System,Minnesota,Wayzata,55391,United States,2013,Postmarket Surv. and Epidemiology,NAI,SCA Pharmaceuticals,4/2/2014,4,2,2014,Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
877947,21 CFR 211.42(c)(10)(vi),Equipment to control conditions,New Mexico,Los Alamos,87545,United States,2013,Drug Quality Assurance,VAI,SCA Pharmaceuticals,4/2/2014,4,2,2014,Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
877947,21 CFR 211.56(a),"Sanitation--buildings not clean, free of infestation",Texas,San Antonio,78215,United States,2013,Drug Quality Assurance,NAI,SCA Pharmaceuticals,4/2/2014,4,2,2014,"Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition."
877947,21 CFR 211.113(b),Validation lacking for sterile drug products,Washington,Vancouver,98684,United States,2013,Drug Quality Assurance,VAI,SCA Pharmaceuticals,4/2/2014,4,2,2014,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
874864,21 CFR 211.100(b),Procedure Deviations Recorded and Justified,California,Irvine,92618,United States,2013,Bioresearch Monitoring,VAI,"TG United, Inc.",4/1/2014,4,1,2014,Deviations from written production and process control procedures are not recorded and justified.
874864,21 CFR 211.166(b),Adequate number of batches on stability,New Jersey,Pennsauken,8109,United States,2013,Drug Quality Assurance,NAI,"TG United, Inc.",4/1/2014,4,1,2014,An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
874864,21 CFR 211.192,"Investigations of discrepancies, failures",Texas,Austin,78705,United States,2013,Bioresearch Monitoring,NAI,"TG United, Inc.",4/1/2014,4,1,2014,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
874864,21 CFR 211.198(a),Complaint Handling Procedure,New York,Patchogue,11772,United States,2013,Drug Quality Assurance,NAI,"TG United, Inc.",4/1/2014,4,1,2014,Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.
874864,21 CFR 211.204,Returned drug procedures in writing and followed,Maryland,Chevy Chase,20815,United States,2013,Bioresearch Monitoring,NAI,"TG United, Inc.",4/1/2014,4,1,2014,"Procedures describing the holding, testing, and reprocessing of returned drug products are not in writing and followed."
874866,21 CFR 211.63,"Equipment Design, Size and Location",Illinois,Round Lake,60073,United States,2013,Drug Quality Assurance,NAI,"TG United, Inc.",4/1/2014,4,1,2014,"Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its cleaning and maintenance."
874866,21 CFR 211.166(b),Adequate number of batches on stability,Puerto Rico,Canovanas,729,United States,2013,Drug Quality Assurance,VAI,"TG United, Inc.",4/1/2014,4,1,2014,An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
874866,21 CFR 211.198(a),Complaint Handling Procedure,Michigan,Kalamazoo,49009,United States,2013,Bioresearch Monitoring,NAI,"TG United, Inc.",4/1/2014,4,1,2014,Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.
874866,21 CFR 211.204,Returned drug procedures in writing and followed,Texas,Houston,77030,United States,2013,Bioresearch Monitoring,NAI,"TG United, Inc.",4/1/2014,4,1,2014,"Procedures describing the holding, testing, and reprocessing of returned drug products are not in writing and followed."
874869,21 CFR 211.166(b),Adequate number of batches on stability,Pennsylvania,Bethlehem,18017,United States,2013,Drug Quality Assurance,VAI,"TG United, Inc.",4/1/2014,4,1,2014,An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
874869,21 CFR 211.192,"Investigations of discrepancies, failures",Texas,Houston,77030,United States,2013,Bioresearch Monitoring,NAI,"TG United, Inc.",4/1/2014,4,1,2014,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
874818,21 CFR 211.28(a),Protective Apparel Not Worn,Missouri,Kansas City,64153,United States,2013,Drug Quality Assurance,NAI,US Compounding Inc,3/27/2014,3,27,2014,Protective apparel is not worn as necessary to protect drug products from contamination.
874818,21 CFR 211.42(c)(10)(v),Cleaning System,California,Chatsworth,91311,United States,2013,Drug Quality Assurance,VAI,US Compounding Inc,3/27/2014,3,27,2014,Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
874818,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Maryland,Owings Mills,21117,United States,2013,Bioresearch Monitoring,NAI,US Compounding Inc,3/27/2014,3,27,2014,"Equipment and utensils are not sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
874818,21 CFR 211.113(b),Procedures for sterile drug products,New Jersey,Pennsauken,8110,United States,2013,Drug Quality Assurance,VAI,US Compounding Inc,3/27/2014,3,27,2014,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
874818,21 CFR 211.165(a),Testing and release for distribution,Texas,Arlington,76014,United States,2013,Bioresearch Monitoring,VAI,US Compounding Inc,3/27/2014,3,27,2014,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
874818,21 CFR 211.167(a),Sterility/pyrogen-free testing,New York,Norwich,13815,United States,2013,Drug Quality Assurance,NAI,US Compounding Inc,3/27/2014,3,27,2014,Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
871040,21 CFR 211.166(a),Written program not followed,Florida,Tallahassee,32304,United States,2013,Drug Quality Assurance,VAI,Mylan Pharmaceuticals Inc.,3/21/2014,3,21,2014,The written stability testing program is not followed.
871040,21 CFR 211.194(e),Stability testing records not  included,Colorado,Denver,80216,United States,2013,Drug Quality Assurance,VAI,Mylan Pharmaceuticals Inc.,3/21/2014,3,21,2014,Laboratory records do not include complete records of all stability testing performed.
872604,21 CFR 211.28(a),Clothing appropriate for duties performed,Missouri,Creve Coeur,63141,United States,2013,Bioresearch Monitoring,NAI,John W Hollis Inc,3/21/2014,3,21,2014,"Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform."
872604,21 CFR 211.42(a),"Buildings of Suitable Size, Construction, Location",Washington,Fife,98424,United States,2013,Drug Quality Assurance,NAI,John W Hollis Inc,3/21/2014,3,21,2014,"Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction and location to facilitate cleaning, maintenance, and proper operations."
872604,21 CFR 211.42(c)(10)(iii),Air Supply,New York,Brookhaven,11719,United States,2013,Drug Quality Assurance,VAI,John W Hollis Inc,3/21/2014,3,21,2014,Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
872604,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Illinois,Chicago,60647,United States,2013,Unapproved and Misbranded Drugs,VAI,John W Hollis Inc,3/21/2014,3,21,2014,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
872604,21 CFR 211.84(a),Components withheld from use pending release,Maryland,Rockville,20850,United States,2013,Bioresearch Monitoring,NAI,John W Hollis Inc,3/21/2014,3,21,2014,"Each lot of components, drug product containers, and closures is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit."
872604,21 CFR 211.94(c),"Containers & Closures Clean, Sterilized, Pyrogen-free",California,Goleta,93117,United States,2013,Drug Quality Assurance,VAI,John W Hollis Inc,3/21/2014,3,21,2014,Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
872604,21 CFR 211.113(b),Validation lacking for sterile drug products,California,Goleta,93117,United States,2013,Unapproved and Misbranded Drugs,VAI,John W Hollis Inc,3/21/2014,3,21,2014,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
872604,21 CFR 211.160(b)(4),Establishment of calibration procedures,Ohio,Dayton,45417,United States,2013,Bioresearch Monitoring,NAI,John W Hollis Inc,3/21/2014,3,21,2014,"Procedures describing the calibration of instruments, apparatus, gauges and recording devices are not written or followed."
872604,21 CFR 211.165(a),Testing and release for distribution,Texas,San Antonio,78229,United States,2013,Bioresearch Monitoring,VAI,John W Hollis Inc,3/21/2014,3,21,2014,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
872604,21 CFR 211.166(a),Lack of written stability program,Puerto Rico,Gurabo,778,United States,2013,Drug Quality Assurance,VAI,John W Hollis Inc,3/21/2014,3,21,2014,There is no written testing program designed to assess the stability characteristics of drug products.
872604,21 CFR 211.167(a),Sterility/pyrogen-free testing,New York,Holtsville,11742,United States,2013,Drug Quality Assurance,OAI,John W Hollis Inc,3/21/2014,3,21,2014,Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
872208,21 CFR 211.68(b),Computer control of master formula records,Minnesota,Eagan,55121,United States,2013,Drug Quality Assurance,VAI,"Ohm Laboratories, Inc.",3/18/2014,3,18,2014,Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
870308,21 CFR 211.28(a),Clothing appropriate for duties performed,Texas,Fort Worth,76118,United States,2013,Unapproved and Misbranded Drugs,NAI,"KRS Global Biotechnology, Inc",3/17/2014,3,17,2014,Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.
870308,21 CFR 211.42(c)(10)(iii),Air Supply,California,Vacaville,95687,United States,2013,Bioresearch Monitoring,VAI,"KRS Global Biotechnology, Inc",3/17/2014,3,17,2014,Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
869135,21 CFR 211.28(a),Clothing appropriate for duties performed,New York,Albany,12208,United States,2013,Bioresearch Monitoring,NAI,Wells Pharmacy Network LLC,3/7/2014,3,7,2014,Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.
869135,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,New Jersey,Cherry Hill,8003,United States,2013,Drug Quality Assurance,VAI,Wells Pharmacy Network LLC,3/7/2014,3,7,2014,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
869135,21 CFR 211.42(c)(10)(v),Cleaning System,New York,New York,10040,United States,2013,Unapproved and Misbranded Drugs,OAI,Wells Pharmacy Network LLC,3/7/2014,3,7,2014,Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
869135,21 CFR 211.160(b)(4),Establishment of calibration procedures,Pennsylvania,Philadelphia,19104,United States,2013,Bioresearch Monitoring,NAI,Wells Pharmacy Network LLC,3/7/2014,3,7,2014,"Procedures describing the calibration of instruments, apparatus, gauges and recording devices are not written or followed."
869135,21 CFR 211.198(a),Complaint Handling Procedure,New Jersey,Hamilton,8691,United States,2013,Drug Quality Assurance,NAI,Wells Pharmacy Network LLC,3/7/2014,3,7,2014,Procedures describing the handling of written and oral complaints related to drug products are not written or followed.
869831,21 CFR 211.28(a),Protective Apparel Not Worn,Florida,Riviera Beach,33404,United States,2013,Drug Quality Assurance,VAI,"Central Admixture Pharmacy Services, Inc.",2/20/2014,2,20,2014,Protective apparel is not worn as necessary to protect drug products from contamination.
869831,21 CFR 211.113(b),Procedures for sterile drug products,South Carolina,Charleston,29405,United States,2013,Drug Quality Assurance,NAI,"Central Admixture Pharmacy Services, Inc.",2/20/2014,2,20,2014,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
869831,21 CFR 211.160(b),Scientifically sound laboratory controls,Louisiana,Shreveport,71103,United States,2013,Drug Quality Assurance,VAI,"Central Admixture Pharmacy Services, Inc.",2/20/2014,2,20,2014,"Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that components conform to appropriate standards of identity, strength, quality and purity."
869831,21 CFR 211.160(b)(3),"Drug products - samples representative, identified properly",California,Camarillo,93012,United States,2013,Drug Quality Assurance,VAI,"Central Admixture Pharmacy Services, Inc.",2/20/2014,2,20,2014,Samples taken of drug products for determination of conformance to written specifications are not representative.
869831,21 CFR 211.192,"Investigations of discrepancies, failures",New York,Deer Park,11729,United States,2013,Drug Quality Assurance,VAI,"Central Admixture Pharmacy Services, Inc.",2/20/2014,2,20,2014,There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
864714,21 CFR 211.84(a),Components withheld from use pending release,California,Colton,92324,United States,2013,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,2/11/2014,2,11,2014,"Each lot of drug product containers and closures is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit."
864714,21 CFR 211.110(a),Control procedures to monitor and validate performance,Michigan,Saginaw,48601,United States,2013,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,2/11/2014,2,11,2014,Control procedures are not established which monitor the output of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
864714,21 CFR 314.81(b)(1)(ii),"Contamination, chemical or physical change, deterioration",Pennsylvania,Philadelphia,19104,United States,2013,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,2/11/2014,2,11,2014,"An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning significant chemical, physical, or other change or deterioration in a distributed drug product."
864887,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Kansas,Kansas City,66105,United States,2013,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,1/24/2014,1,24,2014,The responsibilities and procedures applicable to the quality control unit are not fully followed.
864887,21 CFR 211.67(c),Cleaning/maintenance records not kept,Ohio,Columbus,43229,United States,2013,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,1/24/2014,1,24,2014,Records are not kept for the cleaning of equipment.
864887,21 CFR 211.160(b),Scientifically sound laboratory controls,Ohio,Columbus,43213,United States,2013,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,1/24/2014,1,24,2014,"Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity."
863164,21 CFR 211.22(a),"Approve or reject components, products",Washington,Bellevue,98006,United States,2013,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,1/23/2014,1,23,2014,The quality control unit lacks the responsibility and authority to reject all drug products.
863164,21 CFR 211.22(c),Approve or reject procedures or specs,Washington,Bellevue,98006,United States,2013,Unapproved and Misbranded Drugs,VAI,Baxter Healthcare Corporation,1/23/2014,1,23,2014,The quality control unit lacks responsibility to approve all procedures or specifications impacting on the quality and purity of drug products.
863164,21 CFR 211.68(a),Calibration/Inspection/Checking not done,Florida,Aventura,33180,United States,2013,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,1/23/2014,1,23,2014,Routine calibration and inspection of electronic equipment is not performed according to a written program designed to assure proper performance.
863164,21 CFR 211.84(d)(2),Establish reliability of supplier's C of A,Washington,Bellevue,98005,United States,2013,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,1/23/2014,1,23,2014,Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
863164,21 CFR 211.110(a),Control procedures to monitor and validate performance,Washington,Bellevue,98005,United States,2013,Unapproved and Misbranded Drugs,VAI,Baxter Healthcare Corporation,1/23/2014,1,23,2014,Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
863693,21 CFR 211.192,"Investigations of discrepancies, failures",California,Laguna Hills,92653,United States,2013,Bioresearch Monitoring,VAI,Sage Products Inc,1/15/2014,1,15,2014,There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
860977,21 CFR 211.100(a),"Changes to Procedures Not Reviewed, Approved",Nebraska,Kearney,68847,United States,2013,Bioresearch Monitoring,NAI,"Lannett Company, Inc.",12/23/2013,12,23,2013,"Changes to written procedures are not drafted, reviewed and approved by the appropriate organizational unit and reviewed and approved by the quality control unit."
860977,21 CFR 211.110(a),Written in-process control procedures,Minnesota,Elk River,55330,United States,2013,Bioresearch Monitoring,NAI,"Lannett Company, Inc.",12/23/2013,12,23,2013,"Written procedures are not established and followed that describe the in-process controls, tests, and examinations to be conducted on appropriate samples of in-process materials of each batch."
860977,21 CFR 211.142(b),Storage under appropriate conditions,New York,Carmel,10512,United States,2013,Drug Quality Assurance,VAI,"Lannett Company, Inc.",12/23/2013,12,23,2013,"Drug products are not stored under appropriate conditions of temperature so that their identity, strength, quality, and purity are not affected."
855209,21 CFR 212.50(c)(10),Initials or signatures,Texas,Rosenberg,77471,United States,2013,Drug Quality Assurance,VAI,Cardinal Health,11/14/2013,11,14,2013,Your batch production and control records did not include the initials or signatures of persons performing or checking each significant step in the operation.
853222,21 CFR 211.25(a),"Training--operations, GMPs, written procedures",Florida,North Miami,33161,United States,2013,Bioresearch Monitoring,NAI,Cantrell Drug Company,11/4/2013,11,4,2013,Employees are not given training in the particular operations they perform as part of their function.
853222,21 CFR 211.84(d)(1),Identity Testing of Each Component,North Carolina,Greenville,27834,United States,2013,Drug Quality Assurance,NAI,Cantrell Drug Company,11/4/2013,11,4,2013,"The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist."
853222,21 CFR 211.87,Retest of approved components/containers/closures,Connecticut,Manchester,6040,United States,2013,Bioresearch Monitoring,VAI,Cantrell Drug Company,11/4/2013,11,4,2013,"Approved drug product containers and closures are not retested or reexamined as appropriate for identity, strength, quality and purity after exposure to conditions that might have an adverse effect with subsequent approval or rejection by the quality control unit."
853222,21 CFR 211.94(c),"Containers & Closures Clean, Sterilized, Pyrogen-free",Oklahoma,Enid,73701,United States,2013,Drug Quality Assurance,VAI,Cantrell Drug Company,11/4/2013,11,4,2013,Drug product containers and closures were not clean to assure that they are suitable for their intended use.
853222,21 CFR 211.113(b),Validation lacking for sterile drug products,Puerto Rico,Arecibo,688,United States,2013,Drug Quality Assurance,VAI,Cantrell Drug Company,11/4/2013,11,4,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
853222,21 CFR 211.160(b),Scientifically sound laboratory controls,California,Fountain Valley,92708,United States,2013,Drug Quality Assurance,NAI,Cantrell Drug Company,11/4/2013,11,4,2013,"Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity."
853863,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Pennsylvania,Pittsburgh,15213,United States,2013,Bioresearch Monitoring,VAI,AstraZeneca Pharmaceuticals LP,10/25/2013,10,25,2013,The responsibilities and procedures applicable to the quality control unit are not in writing.
853863,21 CFR 211.198(b)(2),"Written record of complaint to include findings, follow-up",New York,Grand Island,14072,United States,2013,Drug Quality Assurance,OAI,AstraZeneca Pharmaceuticals LP,10/25/2013,10,25,2013,Written records of investigation of a drug complaint do not include the follow-up.
852610,21 CFR 211.22(d),"Procedures not  in writing, fully followed",South Carolina,Columbia,29203,United States,2013,Drug Quality Assurance,NAI,Apotex Inc.,8/20/2013,8,20,2013,The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
852610,21 CFR 211.46(b),Equipment for Environmental Control,Missouri,Saint Peters,63376,United States,2013,Drug Quality Assurance,NAI,Apotex Inc.,8/20/2013,8,20,2013,"Equipment for adequate control over temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product."
852610,21 CFR 211.100(b),SOPs not followed / documented,California,Commerce,90040,United States,2013,Drug Quality Assurance,VAI,Apotex Inc.,8/20/2013,8,20,2013,Written production and process control procedures are not followed in the execution of production and process control functions.
852610,21 CFR 211.113(b),Procedures for sterile drug products,West Virginia,Morgantown,26505,United States,2013,Drug Quality Assurance,NAI,Apotex Inc.,8/20/2013,8,20,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
852610,21 CFR 211.192,"Investigations of discrepancies, failures",Maryland,Bethesda,20892,United States,2013,Bioresearch Monitoring,NAI,Apotex Inc.,8/20/2013,8,20,2013,There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
844132,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Florida,Winter Springs,32708,United States,2013,Unapproved and Misbranded Drugs,OAI,"Lannett Company, Inc.",8/6/2013,8,6,2013,The responsibilities and procedures applicable to the quality control unit are not fully followed.
844132,21 CFR 211.46(b),Equipment for Environmental Control,New York,Ronkonkoma,11779,United States,2013,Unapproved and Misbranded Drugs,VAI,"Lannett Company, Inc.",8/6/2013,8,6,2013,"Equipment for adequate control over air pressure, dust, humidity, and temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product."
844132,21 CFR 211.63,"Equipment Design, Size and Location",Texas,San Antonio,78229,United States,2013,Bioresearch Monitoring,NAI,"Lannett Company, Inc.",8/6/2013,8,6,2013,"Equipment used in the manufacture, processing, packing or holding of drug products is not suitably located to facilitate operations for its intended use."
844132,21 CFR 211.110(a),Control procedures to monitor and validate performance,Kentucky,Lexington,40517,United States,2013,Bioresearch Monitoring,VAI,"Lannett Company, Inc.",8/6/2013,8,6,2013,Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
844132,21 CFR 211.110(b),In-process materials specifications,Florida,Deland,32720,United States,2013,Bioresearch Monitoring,NAI,"Lannett Company, Inc.",8/6/2013,8,6,2013,In-process specifications are not derived from previous acceptable process average and process variability estimates where possible and determined by the application of suitable statistical procedures where appropriate.
844026,21 CFR 211.58,Buildings not maintained in good state of repair,Texas,Grand Saline,75140,United States,2013,Drug Quality Assurance,NAI,"Aidapak Services, LLC",7/31/2013,7,31,2013,Buildings used in the packing and holding of a drug product are not maintained in a good state of repair.
844026,21 CFR 211.67(b),Written procedures not established/followed,South Carolina,Easley,29640,United States,2013,Drug Quality Assurance,NAI,"Aidapak Services, LLC",7/31/2013,7,31,2013,"Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product."
844026,21 CFR 211.125(a),Strict control not exercised over labeling issued,New York,New York,10017,United States,2013,Drug Quality Assurance,VAI,"Aidapak Services, LLC",7/31/2013,7,31,2013,Strict control is not exercised over labeling issued for use in drug product labeling operations.
844026,21 CFR 211.130,"Procedures are written, and followed",New York,New York,10017,United States,2013,Postmarket Surv. and Epidemiology,VAI,"Aidapak Services, LLC",7/31/2013,7,31,2013,Procedures designed to assure that correct labels are used for drug products are not written and followed.
844026,21 CFR 211.130(d),Examination of packaging and labeling,California,Los Angeles,90059,United States,2013,Drug Quality Assurance,NAI,"Aidapak Services, LLC",7/31/2013,7,31,2013,Examination of packaging and labeling materials for suitability and correctness before packaging operations is not performed and not documented in the batch production records.
844026,21 CFR 211.130(e),Packaging line inspection before use,Missouri,Union,63084,United States,2013,Drug Quality Assurance,NAI,"Aidapak Services, LLC",7/31/2013,7,31,2013,Inspection of the packaging and labeling facilities immediately before use is not done to assure that all drug products have been removed from previous operations.
844026,21 CFR 211.170(b),"Reserve samples identified, representative, stored",Florida,Hialeah,33014,United States,2013,Drug Quality Assurance,VAI,"Aidapak Services, LLC",7/31/2013,7,31,2013,Reserve drug product samples are not appropriately identified.
844026,21 CFR 211.192,Written record of investigation incomplete,Florida,Hialeah,33014,United States,2013,Unapproved and Misbranded Drugs,VAI,"Aidapak Services, LLC",7/31/2013,7,31,2013,Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
843527,21 CFR 211.42(c)(10)(iii),Air Supply,Ohio,Sharonville,45241,United States,2013,Drug Quality Assurance,VAI,Wells Pharmacy Network LLC,7/26/2013,7,26,2013,Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
843527,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Ohio,Cincinnati,45237,United States,2013,Drug Quality Assurance,VAI,Wells Pharmacy Network LLC,7/26/2013,7,26,2013,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
843527,21 CFR 211.68(a),Calibration/Inspection/Checking not done,New Jersey,Cedar Grove,7009,United States,2013,Drug Quality Assurance,VAI,Wells Pharmacy Network LLC,7/26/2013,7,26,2013,Routine calibration and inspection of mechanical equipment is not performed according to a written program designed to assure proper performance.
843527,21 CFR 211.113(b),Procedures for sterile drug products,New Jersey,Bridgewater,8807,United States,2013,Bioresearch Monitoring,NAI,Wells Pharmacy Network LLC,7/26/2013,7,26,2013,"Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed."
843527,21 CFR 211.113(b),Validation lacking for sterile drug products,California,Fresno,93701,United States,2013,Bioresearch Monitoring,OAI,Wells Pharmacy Network LLC,7/26/2013,7,26,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
843527,21 CFR 211.165(a),Testing and release for distribution,Ohio,Columbus,43228,United States,2013,Drug Quality Assurance,NAI,Wells Pharmacy Network LLC,7/26/2013,7,26,2013,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
843527,21 CFR 211.166(a),Lack of written stability program,Ohio,Cincinnati,45237,United States,2013,Drug Quality Assurance,VAI,Wells Pharmacy Network LLC,7/26/2013,7,26,2013,There is no written testing program designed to assess the stability characteristics of drug products.
843527,21 CFR 211.192,"Investigations of discrepancies, failures",Florida,Fort Lauderdale,33308,United States,2013,Bioresearch Monitoring,NAI,Wells Pharmacy Network LLC,7/26/2013,7,26,2013,There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
841366,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Tennessee,Cookeville,38506,United States,2013,Drug Quality Assurance,NAI,"Beacon Hill Medical Pharmacy, P.C.",7/19/2013,7,19,2013,The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
841366,21 CFR 211.63,"Equipment Design, Size and Location",New York,Middleburgh,12122,United States,2013,Drug Quality Assurance,NAI,"Beacon Hill Medical Pharmacy, P.C.",7/19/2013,7,19,2013,"Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and suitably located to facilitate operations for its intended use."
841366,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,California,Sacramento,95828,United States,2013,Unapproved and Misbranded Drugs,VAI,"Beacon Hill Medical Pharmacy, P.C.",7/19/2013,7,19,2013,"Equipment and utensils are not cleaned, maintained, and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
841366,21 CFR 211.94(c),"Containers & Closures Clean, Sterilized, Pyrogen-free",California,Carson,90746,United States,2012,Bioresearch Monitoring,NAI,"Beacon Hill Medical Pharmacy, P.C.",7/19/2013,7,19,2013,Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
841366,21 CFR 211.111,Establishment of time limitations,Illinois,Libertyville,60048,United States,2012,Drug Quality Assurance,NAI,"Beacon Hill Medical Pharmacy, P.C.",7/19/2013,7,19,2013,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
841366,21 CFR 211.113(b),Procedures for sterile drug products,North Carolina,Charlotte,28204,United States,2012,Bioresearch Monitoring,NAI,"Beacon Hill Medical Pharmacy, P.C.",7/19/2013,7,19,2013,"Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed."
841366,21 CFR 211.160(a),"Lab controls established, including changes",Ohio,Cincinnati,45246,United States,2012,Bioresearch Monitoring,NAI,"Beacon Hill Medical Pharmacy, P.C.",7/19/2013,7,19,2013,"The establishment of specifications, sampling plans, test procedures, and laboratory control mechanisms including any changes thereto, are not drafted by the appropriate organizational unit and reviewed and approved by the quality control unit."
841366,21 CFR 211.188(b),Batch production and Batch Control Record Requirements,Missouri,Saint Louis,63108,United States,2012,Bioresearch Monitoring,NAI,"Beacon Hill Medical Pharmacy, P.C.",7/19/2013,7,19,2013,The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in processing.
842993,21 CFR 211.194(d),Laboratory equipment calibration records,Illinois,Blue Island,60406,United States,2012,Drug Quality Assurance,VAI,The Procter & Gamble Manufacturing Company,7/18/2013,7,18,2013,Laboratory records do not include complete records of the periodic calibration of laboratory instruments.
839893,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Texas,Alvin,77511,United States,2012,Postmarket Surv. and Epidemiology,VAI,L'Oreal USA Products Inc,6/20/2013,6,20,2013,"Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
839893,21 CFR 211.180(e)(2),Items to cover on annual reviews,Colorado,Fort Collins,80526,United States,2012,Drug Quality Assurance,VAI,L'Oreal USA Products Inc,6/20/2013,6,20,2013,"Written procedures are not followed for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product."
835574,21 CFR 211.100(b),SOPs not followed / documented,Pennsylvania,Levittown,19056,United States,2012,Drug Quality Assurance,VAI,"Blenheim Pharmacal, Inc.",6/19/2013,6,19,2013,Written production and process control procedures are not followed in the execution of production and process control functions.
835574,21 CFR 211.142(b),Storage under appropriate conditions,Virginia,Lynchburg,24502,United States,2012,Drug Quality Assurance,VAI,"Blenheim Pharmacal, Inc.",6/19/2013,6,19,2013,"Drug products are not stored under appropriate conditions of temperature and humidity so that their identity, strength, quality, and purity are not affected."
838639,21 CFR 211.22(a),Lack of quality control unit,Mississippi,Olive Branch,38654,United States,2012,Postmarket Surv. and Epidemiology,VAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,There is no quality control unit.
838639,21 CFR 211.28(a),Protective Apparel Not Worn,Pennsylvania,Philadelphia,19104,United States,2012,Bioresearch Monitoring,VAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,Protective apparel is not worn as necessary to protect drug products from contamination.
838639,21 CFR 211.42(a),"Buildings of Suitable Size, Construction, Location",California,South San Francisco,94080,United States,2012,Postmarket Surv. and Epidemiology,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,"Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable size, construction, and location to facilitate cleaning, maintenance, and proper operations."
838639,21 CFR 211.56(a),"Sanitation--buildings not clean, free of infestation",Connecticut,Cheshire,6410,United States,2012,Drug Quality Assurance,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,"Buildings used in the manufacture, processing, packing or holding of drug products are not free of infestation by rodents, birds insects, and other vermin."
838639,21 CFR 211.56(b),Written sanitation procedures lacking,Massachusetts,Cambridge,2142,United States,2012,Bioresearch Monitoring,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,"There is a lack of written procedures assigning responsibility, providing cleaning schedules, and describing in sufficient detail the methods, equipment and materials to be used for sanitation."
838639,21 CFR 211.63,"Equipment Design, Size and Location",New Jersey,Lodi,7644,United States,2012,Drug Quality Assurance,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,"Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use."
838639,21 CFR 211.68(a),Calibration/Inspection/Checking not done,New York,New York,10065,United States,2012,Bioresearch Monitoring,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,Routine calibration and inspection of electronic equipment is not performed according to a written program designed to assure proper performance.
838639,21 CFR 211.80(b),Handling and Storage to Prevent Contamination,Michigan,Holland,49424,United States,2012,Drug Quality Assurance,VAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,There was a failure to handle and store drug product containers at all times in a manner to prevent contamination.
838639,21 CFR 211.84(a),Components withheld from use pending release,North Carolina,Durham,27701,United States,2012,Bioresearch Monitoring,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,"Each lot of components, drug product containers, and closures is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit."
838639,21 CFR 211.89,Quarantine of Rejected Components et. al.,Virginia,Elkton,22827,United States,2012,Drug Quality Assurance,VAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,Rejected components are not controlled under a quarantine system designed to prevent their use in manufacturing or processing operations for which they are unsuitable.
838639,21 CFR 211.100(a),Absence of Written Procedures,Kentucky,Fountain Run,42133,United States,2012,Drug Quality Assurance,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
838639,21 CFR 211.111,Establishment of time limitations,Texas,Austin,78728,United States,2012,Drug Quality Assurance,VAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
838639,21 CFR 211.113(b),Procedures for sterile drug products,New York,Westbury,11590,United States,2012,Drug Quality Assurance,VAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
838639,21 CFR 211.113(b),Validation lacking for sterile drug products,Pennsylvania,Philadelphia,19112,United States,2012,Drug Quality Assurance,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
838639,21 CFR 211.165(a),Testing and release for distribution,Florida,Miami,33135,United States,2012,Bioresearch Monitoring,VAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
838639,21 CFR 211.167(a),Sterility/pyrogen-free testing,Minnesota,Eden Prairie,55344,United States,2012,Drug Quality Assurance,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
838639,21 CFR 211.170(a),Active ingredient retained sample kept,Minnesota,Brooklyn Park,55428,United States,2012,Drug Quality Assurance,NAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,A sample which is representative of each lot in each shipment of each active ingredient is not retained.
838639,21 CFR 211.182,Written records kept in individual logs,Texas,San Antonio,78215,United States,2012,Bioresearch Monitoring,VAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,"Written records of major equipment cleaning, maintenance, and use are not included in individual equipment logs."
838639,21 CFR 211.188,"Prepared for each batch, include complete information",California,Los Angeles,90095,United States,2012,Drug Quality Assurance,VAI,"Main Street Family Pharmacy, LLC",6/11/2013,6,11,2013,Batch production and control records do not include complete information relating to the production and control of each batch.
837414,21 CFR 211.68(a),Calibration/Inspection/Checking not done,Indiana,Columbus,47201,United States,2012,Drug Quality Assurance,VAI,"Sun Pharmaceutical Industries, Inc.",5/16/2013,5,16,2013,"Routine calibration, inspection, and checking of automatic, mechanical, and electronic equipment is not performed according to a written program designed to assure proper performance."
828005,21 CFR 211.100(a),Absence of Written Procedures,Texas,Dallas,75220,United States,2012,Drug Quality Assurance,VAI,"Akorn, Inc.",5/3/2013,5,3,2013,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
828005,21 CFR 211.160(a),"Lab controls established, including changes",Rhode Island,Providence,2907,United States,2012,Drug Quality Assurance,VAI,"Akorn, Inc.",5/3/2013,5,3,2013,"The establishment of specifications, standards, sampling plans, test procedures, and laboratory control mechanisms including any changes thereto, are not drafted by the appropriate organizational unit and reviewed and approved by the quality control unit."
828005,21 CFR 211.180(e),Records reviewed annually,California,Rancho Cucamonga,91730,United States,2012,Unapproved and Misbranded Drugs,VAI,"Akorn, Inc.",5/3/2013,5,3,2013,Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.
828005,21 CFR 211.188,"Prepared for each batch, include complete information",New York,Rochester,14609,United States,2012,Bioresearch Monitoring,NAI,"Akorn, Inc.",5/3/2013,5,3,2013,Batch production and control records do not include complete information relating to the production and control of each batch.
828005,21 CFR 211.192,No written record of investigation,Colorado,Denver,80204,United States,2012,Postmarket Surv. and Epidemiology,NAI,"Akorn, Inc.",5/3/2013,5,3,2013,Written records are not always made of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications.
832023,21 CFR 314.81(b)(1)(ii),"Contamination, chemical or physical change, deterioration",Washington,Fife,98424,United States,2012,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,4/19/2013,4,19,2013,"An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning significant chemical, physical, or other change or deterioration in a distributed drug product."
827465,21 CFR 211.198(a),Complaint Handling Procedure,New York,Farmingdale,11735,United States,2012,Unapproved and Misbranded Drugs,VAI,"Taro Pharmaceuticals U.S.A., Inc.",4/18/2013,4,18,2013,Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.
827465,21 CFR 314.80(b),Failure to develop written procedures,New Mexico,Albuquerque,87106,United States,2012,Bioresearch Monitoring,NAI,"Taro Pharmaceuticals U.S.A., Inc.",4/18/2013,4,18,2013,Written procedures have not been developed for the surveillance and evaluation of post marketing adverse drug experiences.
827465,21 CFR 314.80(c),Failure by applicant to report ADE,Kentucky,Louisville,40299,United States,2012,Unapproved and Misbranded Drugs,NAI,"Taro Pharmaceuticals U.S.A., Inc.",4/18/2013,4,18,2013,Adverse drug experience information has not been reported to FDA.
825163,21 CFR 211.28(a),Clothing appropriate for duties performed,Puerto Rico,Barceloneta,617,United States,2012,Drug Quality Assurance,VAI,"Downing Labs, LLC",4/16/2013,4,16,2013,Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.
825163,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Massachusetts,Wilmington,1887,United States,2012,Drug Quality Assurance,NAI,"Downing Labs, LLC",4/16/2013,4,16,2013,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
825163,21 CFR 211.42(c)(10)(v),Cleaning System,New York,Malone,12953,United States,2012,Drug Quality Assurance,VAI,"Downing Labs, LLC",4/16/2013,4,16,2013,Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
825163,21 CFR 211.42(c)(10)(vi),Equipment to control conditions,New York,Malone,12953,United States,2012,Unapproved and Misbranded Drugs,OAI,"Downing Labs, LLC",4/16/2013,4,16,2013,Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
825163,21 CFR 211.100(a),Absence of Written Procedures,Maine,Augusta,4330,United States,2012,Bioresearch Monitoring,NAI,"Downing Labs, LLC",4/16/2013,4,16,2013,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
825163,21 CFR 211.165(b),Microbiological testing,New Jersey,Raritan,8869,United States,2012,Drug Quality Assurance,NAI,"Downing Labs, LLC",4/16/2013,4,16,2013,Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
825163,21 CFR 211.186(b)(9),"Complete instructions, procedures, specifications et. al.",New Jersey,Piscataway,8854,United States,2012,Drug Quality Assurance,NAI,"Downing Labs, LLC",4/16/2013,4,16,2013,Master production and control records lack complete manufacturing and control instructions.
825163,21 CFR 211.192,"Investigations of discrepancies, failures",New York,Patchogue,11772,United States,2012,Drug Quality Assurance,NAI,"Downing Labs, LLC",4/16/2013,4,16,2013,There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
827045,21 CFR 211.25(a),GMP Training Frequency,Ohio,Cincinnati,45213,United States,2012,Drug Quality Assurance,VAI,Clinical Specialties Compounding Pharmacy,4/2/2013,4,2,2013,GMP training is not conducted on a continuing basis and with sufficient frequency to assure that employees remain familiar with CGMP requirements applicable to them.
827045,21 CFR 211.25(c),Inadequate number of  personnel,Ohio,Cincinnati,45213,United States,2012,Prescription Drug Advertising and Labelling,NAI,Clinical Specialties Compounding Pharmacy,4/2/2013,4,2,2013,The number of qualified personnel is inadequate to perform the manufacture and processing of each drug product.
827045,21 CFR 211.42(b),Product flow through building is inadequate,California,Burbank,91504,United States,2012,Drug Quality Assurance,VAI,Clinical Specialties Compounding Pharmacy,4/2/2013,4,2,2013,"The flow of components, drug product containers, in-process materials, and drug products though the building is not designed to prevent contamination."
827045,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,California,Burbank,91504,United States,2012,Drug Quality Assurance,VAI,Clinical Specialties Compounding Pharmacy,4/2/2013,4,2,2013,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
827045,21 CFR 211.42(c)(10)(v),Cleaning System,California,Burbank,91504,United States,2012,Drug Quality Assurance,VAI,Clinical Specialties Compounding Pharmacy,4/2/2013,4,2,2013,Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
827045,21 CFR 211.113(b),Validation lacking for sterile drug products,Florida,Key Colony Beach,33051,United States,2012,Unapproved and Misbranded Drugs,OAI,Clinical Specialties Compounding Pharmacy,4/2/2013,4,2,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
827045,21 CFR 211.150(b),Recall facilitation,New Jersey,Edison,8817,United States,2012,Drug Quality Assurance,VAI,Clinical Specialties Compounding Pharmacy,4/2/2013,4,2,2013,"A system by which the distribution of each lot of drug product can be readily determined to facilitate its recall if necessary, has not been established."
827045,21 CFR 211.166(a),Lack of written stability program,California,Irvine,92618,United States,2012,Drug Quality Assurance,NAI,Clinical Specialties Compounding Pharmacy,4/2/2013,4,2,2013,There is no written testing program designed to assess the stability characteristics of drug products.
823433,21 CFR 314.80(c)(1)(i),Late submission of 15-day report,Arizona,Scottsdale,85260,United States,2012,Drug Quality Assurance,NAI,Merck Sharp & Dohme Corp.,3/26/2013,3,26,2013,Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
823212,21 CFR 211.113(a),Procedures for non-sterile drug products,California,Irvine,92618,United States,2012,Drug Quality Assurance,NAI,"Lannett Company, Inc.",3/25/2013,3,25,2013,Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established and written.
824093,21 CFR 211.28(a),Protective Apparel Not Worn,North Carolina,Asheville,28806,United States,2012,Drug Quality Assurance,NAI,"Medaus, Inc.",3/22/2013,3,22,2013,Protective apparel is not worn as necessary to protect drug products from contamination.
824093,21 CFR 211.111,Establishment of time limitations,South Carolina,Taylors,29687,United States,2012,Bioresearch Monitoring,VAI,"Medaus, Inc.",3/22/2013,3,22,2013,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
824093,21 CFR 211.113(b),Procedures for sterile drug products,Connecticut,Plainville,6062,United States,2012,Drug Quality Assurance,VAI,"Medaus, Inc.",3/22/2013,3,22,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
824093,21 CFR 211.113(b),Validation lacking for sterile drug products,Ohio,Westlake,44145,United States,2012,Drug Quality Assurance,VAI,"Medaus, Inc.",3/22/2013,3,22,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
824093,21 CFR 211.142(b),Storage under appropriate conditions,North Carolina,Durham,27709,United States,2012,Drug Quality Assurance,VAI,"Medaus, Inc.",3/22/2013,3,22,2013,"Drug products are not stored under appropriate conditions of temperature and light so that their identity, strength, quality, and purity are not affected."
824093,21 CFR 211.160(b)(1),Incoming lots - conformance to written specs-,Michigan,Hemlock,48626,United States,2012,Drug Quality Assurance,VAI,"Medaus, Inc.",3/22/2013,3,22,2013,"Laboratory controls do not include determination of conformance to appropriate written specifications for the acceptance of each lot within each shipment of components, drug product containers, closures, and drug products used in the manufacture, processing, packing, or holding of drug products."
824093,21 CFR 211.165(a),Testing and release for distribution,California,San Francisco,94111,United States,2012,Drug Quality Assurance,VAI,"Medaus, Inc.",3/22/2013,3,22,2013,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
824093,21 CFR 211.166(b),Adequate number of batches on stability,Arizona,Tempe,85281,United States,2012,Drug Quality Assurance,OAI,"Medaus, Inc.",3/22/2013,3,22,2013,An adequate number of batches of each drug product are not tested to determine an appropriate expiration date.
824093,21 CFR 211.167(a),Sterility/pyrogen-free testing,New Jersey,North Brunswick,8902,United States,2012,Postmarket Surv. and Epidemiology,NAI,"Medaus, Inc.",3/22/2013,3,22,2013,Each batch of drug product purporting to be sterile is not laboratory tested to determine conformance to such requirements.
822999,21 CFR 211.28(a),Clothing appropriate for duties performed,Illinois,Granite City,62040,United States,2012,Drug Quality Assurance,NAI,"FVS Holdings, Inc. dba. Green Valley Drugs",3/15/2013,3,15,2013,Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.
822999,21 CFR 211.42(c),Defined areas of adequate size for operations,Ohio,Canton,44705,United States,2012,Drug Quality Assurance,VAI,"FVS Holdings, Inc. dba. Green Valley Drugs",3/15/2013,3,15,2013,The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.
822999,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Michigan,Saginaw,48602,United States,2012,Bioresearch Monitoring,VAI,"FVS Holdings, Inc. dba. Green Valley Drugs",3/15/2013,3,15,2013,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
822999,21 CFR 211.42(c)(10)(v),Cleaning System,Pennsylvania,Conshohocken,19428,United States,2012,Bioresearch Monitoring,VAI,"FVS Holdings, Inc. dba. Green Valley Drugs",3/15/2013,3,15,2013,Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
822999,21 CFR 211.80(b),Handling and Storage to Prevent Contamination,Wisconsin,Monroe,53566,United States,2012,Drug Quality Assurance,VAI,"FVS Holdings, Inc. dba. Green Valley Drugs",3/15/2013,3,15,2013,There was a failure to handle and store drug product containers at all times in a manner to prevent contamination.
822999,21 CFR 211.113(b),Procedures for sterile drug products,Tennessee,Nashville,37212,United States,2012,Bioresearch Monitoring,VAI,"FVS Holdings, Inc. dba. Green Valley Drugs",3/15/2013,3,15,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
822999,21 CFR 211.113(b),Validation lacking for sterile drug products,Michigan,Bay City,48706,United States,2012,Drug Quality Assurance,NAI,"FVS Holdings, Inc. dba. Green Valley Drugs",3/15/2013,3,15,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
822999,21 CFR 211.166(a),Lack of written stability program,Ohio,Columbus,43229,United States,2012,Drug Quality Assurance,VAI,"FVS Holdings, Inc. dba. Green Valley Drugs",3/15/2013,3,15,2013,There is no written testing program designed to assess the stability characteristics of drug products.
822999,21 CFR 211.192,"Investigations of discrepancies, failures",Nevada,Reno,89509,United States,2012,Unapproved and Misbranded Drugs,VAI,"FVS Holdings, Inc. dba. Green Valley Drugs",3/15/2013,3,15,2013,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
823282,21 CFR 211.28(a),Clothing appropriate for duties performed,California,Livermore,94551,United States,2012,Drug Quality Assurance,VAI,Axium Healthcare Pharmacy dba Balanced Solutions Compounding,3/15/2013,3,15,2013,Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.
823282,21 CFR 211.42(c)(1),Incoming material area,New Jersey,Bellmawr,8031,United States,2012,Drug Quality Assurance,NAI,Axium Healthcare Pharmacy dba Balanced Solutions Compounding,3/15/2013,3,15,2013,"Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the receipt, identification, storage, and withholding from use of components and drug product containers pending sampling, testing, or examination by the quality control unit before release for manufacturing or packaging."
823282,21 CFR 211.42(c)(10)(iv),Environmental Monitoring System,Georgia,Marietta,30060,United States,2012,Bioresearch Monitoring,VAI,Axium Healthcare Pharmacy dba Balanced Solutions Compounding,3/15/2013,3,15,2013,Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
823282,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,California,South San Francisco,94080,United States,2012,Bioresearch Monitoring,NAI,Axium Healthcare Pharmacy dba Balanced Solutions Compounding,3/15/2013,3,15,2013,"Equipment and utensils are not cleaned, maintained, and sanitized at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product."
823282,21 CFR 211.113(b),Procedures for sterile drug products,North Carolina,Winston Salem,27103,United States,2012,Bioresearch Monitoring,NAI,Axium Healthcare Pharmacy dba Balanced Solutions Compounding,3/15/2013,3,15,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
823282,21 CFR 211.113(b),Validation lacking for sterile drug products,Florida,Orlando,32806,United States,2012,Bioresearch Monitoring,OAI,Axium Healthcare Pharmacy dba Balanced Solutions Compounding,3/15/2013,3,15,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
817330,21 CFR 211.100(b),SOPs not followed / documented,Florida,Clearwater,33765,United States,2012,Drug Quality Assurance,NAI,"Par Pharmaceutical, Inc.",2/19/2013,2,19,2013,Written production and process control procedures are not followed in the execution of production and process control functions.
817330,21 CFR 211.110(a),Control procedures to monitor and validate performance,New York,Bohemia,11716,United States,2012,Postmarket Surv. and Epidemiology,NAI,"Par Pharmaceutical, Inc.",2/19/2013,2,19,2013,Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
815426,21 CFR 211.22(d),"Procedures not  in writing, fully followed",New Jersey,Springfield,7081,United States,2012,Bioresearch Monitoring,VAI,"Fresenius Kabi USA, LLC",1/11/2013,1,11,2013,The responsibilities and procedures applicable to the quality control unit are not fully followed.
815426,21 CFR 211.56(a),"Sanitation--buildings not clean, free of infestation",Missouri,Chesterfield,63017,United States,2012,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",1/11/2013,1,11,2013,"Buildings used in the manufacture, processing, packing or holding of drug products are not free of infestation by rodents, birds insects, and other vermin."
815426,21 CFR 211.67(b),Written procedures not established/followed,Massachusetts,Dudley,1571,United States,2012,Drug Quality Assurance,VAI,"Fresenius Kabi USA, LLC",1/11/2013,1,11,2013,"Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product."
815426,21 CFR 211.113(b),Procedures for sterile drug products,Ohio,Bucyrus,44820,United States,2012,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",1/11/2013,1,11,2013,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
815426,21 CFR 211.180(c),Photocopying of records not allowed,Illinois,Tinley Park,60477,United States,2012,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",1/11/2013,1,11,2013,Records or copies of records were not made available for photocopying or other means of reproduction.
815426,21 CFR 211.192,"Investigations of discrepancies, failures",Colorado,Boulder,80301,United States,2012,Drug Quality Assurance,VAI,"Fresenius Kabi USA, LLC",1/11/2013,1,11,2013,There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
815426,21 CFR 314.81(b)(1)(ii),"Contamination, chemical or physical change, deterioration",Massachusetts,Waltham,2453,United States,2012,Bioresearch Monitoring,NAI,"Fresenius Kabi USA, LLC",1/11/2013,1,11,2013,"An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning significant chemical, physical, or other change or deterioration in a distributed drug product."
815426,21 CFR 314.81(b)(2),Timely submission,North Carolina,Charlotte,28217,United States,2012,Drug Quality Assurance,VAI,"Fresenius Kabi USA, LLC",1/11/2013,1,11,2013,An annual report was not submitted within 60 days of the anniversary date of U.S. approval of the application to the FDA division responsible for reviewing the application.
811624,21 CFR 211.100(a),Absence of Written Procedures,Texas,Dallas,75243,United States,2012,Drug Quality Assurance,VAI,Novartis Pharmaceuticals Corp.,12/19/2012,12,19,2012,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
811624,21 CFR 211.180(e)(1),Review of representative number of batches,Tennessee,Cleveland,37323,United States,2012,Drug Quality Assurance,NAI,Novartis Pharmaceuticals Corp.,12/19/2012,12,19,2012,"Written procedures are not followed for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected."
802315,21 CFR 211.22(d),"Procedures not  in writing, fully followed",New Jersey,Lambertville,8530,United States,2012,Postmarket Surv. and Epidemiology,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
802315,21 CFR 211.63,"Equipment Design, Size and Location",Maryland,Easton,21601,United States,2012,Drug Quality Assurance,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,"Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use."
802315,21 CFR 211.68(b),Computer control of master formula records,California,South El Monte,91733,United States,2012,Drug Quality Assurance,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
802315,21 CFR 211.110(a),Control procedures to monitor and validate performance,Pennsylvania,Monroeville,15146,United States,2012,Drug Quality Assurance,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
802315,21 CFR 211.111,Establishment of time limitations,California,Hayward,94544,United States,2012,Drug Quality Assurance,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
802315,21 CFR 211.160(a),"Lab controls established, including changes",Virginia,Chesapeake,23320,United States,2012,Drug Quality Assurance,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,"The establishment of laboratory control mechanisms including any changes thereto, are not drafted by the appropriate organizational unit and reviewed and approved by the quality control unit."
802315,21 CFR 211.160(b),Scientifically sound laboratory controls,California,San Francisco,94117,United States,2012,Bioresearch Monitoring,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,"Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that components, in-process materials, and drug products conform to appropriate standards of identity, strength, quality and purity."
802315,21 CFR 211.165(e),Test methods,California,Hayward,94544,United States,2012,Drug Quality Assurance,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,"The accuracy, sensitivity, specificity, and reproducibility of test methods have not been established."
802315,21 CFR 211.165(f),Failing drug products not rejected,Texas,Houston,77099,United States,2012,Drug Quality Assurance,NAI,Watson Laboratories Inc,11/26/2012,11,26,2012,Drug products failing to meet established quality control criteria are not rejected.
802315,21 CFR 211.166(a)(3),Valid stability test methods,Texas,Houston,77099,United States,2012,Postmarket Surv. and Epidemiology,NAI,Watson Laboratories Inc,11/26/2012,11,26,2012,"The written stability program for drug products does not include reliable, meaningful, and specific test methods."
802315,21 CFR 211.166(a)(4),Testing in same container - closure system,Texas,Houston,77099,United States,2012,Unapproved and Misbranded Drugs,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,The written stability program does not assure testing of the drug product in the same container-closure system as that in which the drug product is marketed.
802315,21 CFR 211.186(b)(1),Product Name and Strength,California,Fullerton,92835,United States,2012,Bioresearch Monitoring,NAI,Watson Laboratories Inc,11/26/2012,11,26,2012,The master production and control records are deficient in that they do not include the name and strength of the drug product and a description of the dosage form.
802315,21 CFR 211.192,"Extent of discrepancy, failure  investigations",Iowa,Des Moines,50313,United States,2012,Drug Quality Assurance,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,Investigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product.
802315,21 CFR 211.192,"Investigations of discrepancies, failures",New Jersey,South Plainfield,7080,United States,2012,Drug Quality Assurance,NAI,Watson Laboratories Inc,11/26/2012,11,26,2012,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
802315,21 CFR 211.192,Written record of investigation incomplete,New Jersey,South Plainfield,7080,United States,2012,Postmarket Surv. and Epidemiology,NAI,Watson Laboratories Inc,11/26/2012,11,26,2012,Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
802315,21 CFR 211.194(a)(2),Suitability of testing methods verified,California,Irvine,92618,United States,2012,Drug Quality Assurance,NAI,Watson Laboratories Inc,11/26/2012,11,26,2012,The suitability of all testing methods is not verified under actual conditions of use.
802315,21 CFR 314.81(b)(1)(ii),"Contamination, chemical or physical change, deterioration",Wyoming,Green River,82935,United States,2012,Drug Quality Assurance,VAI,Watson Laboratories Inc,11/26/2012,11,26,2012,"An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning significant chemical, physical, or other change or deterioration in a distributed drug product."
809535,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Michigan,Warren,48089,United States,2012,Drug Quality Assurance,VAI,Cardinal Health,11/26/2012,11,26,2012,The responsibilities and procedures applicable to the quality control unit are not fully followed.
807963,21 CFR 211.58,Buildings not maintained in good state of repair,Kentucky,Morehead,40351,United States,2012,Bioresearch Monitoring,NAI,Torrent Pharma Inc,11/21/2012,11,21,2012,"Buildings used in the manufacturing, processing, and packing of a drug product are not maintained in a good state of repair."
807963,21 CFR 211.192,"Extent of discrepancy, failure  investigations",Alabama,Arab,35016,United States,2012,Drug Quality Assurance,NAI,Torrent Pharma Inc,11/21/2012,11,21,2012,Investigations of an unexplained discrepancy and a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product.
808425,21 CFR 211.46(b),Equipment for Environmental Control,California,Northridge,91324,United States,2012,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,11/16/2012,11,16,2012,"Equipment for adequate control over micro-organisms is not provided when appropriate for the manufacture, processing, packing or holding of a drug product."
808425,21 CFR 211.56(c),Written procedures lacking for use of pesticides etc.,Tennessee,Nashville,37228,United States,2012,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,11/16/2012,11,16,2012,"Written procedures are lacking for the use of cleaning and sanitizing agents designed to prevent the contamination of equipment, components, drug product containers, closures, and drug products."
808425,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Kansas,Mcpherson,67460,United States,2012,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,11/16/2012,11,16,2012,"Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
808425,21 CFR 211.67(b),Written procedures fail to include,Minnesota,Minnetonka,55305,United States,2012,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,11/16/2012,11,16,2012,Written procedures for cleaning and maintenance fail to include instructions for protection of clean equipment from contamination prior to use and parameters relevant to the operation.
808425,21 CFR 211.67(c),Cleaning/maintenance records not kept,Texas,Grand Prairie,75050,United States,2012,Drug Quality Assurance,OAI,Baxter Healthcare Corporation,11/16/2012,11,16,2012,Records are not kept for the maintenance and cleaning of equipment.
808425,21 CFR 211.100(b),SOPs not followed / documented,Wisconsin,Elkhorn,53121,United States,2012,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,11/16/2012,11,16,2012,Written production and process control procedures are not followed in the execution of production and process control functions.
808425,21 CFR 211.160(b),Scientifically sound laboratory controls,North Dakota,Bismarck,58501,United States,2012,Bioresearch Monitoring,NAI,Baxter Healthcare Corporation,11/16/2012,11,16,2012,"Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity."
808425,21 CFR 211.192,No written record of investigation,Pennsylvania,Warminster,18974,United States,2012,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,11/16/2012,11,16,2012,Written records are not made of investigations into unexplained discrepancies.
808425,21 CFR 211.194(a)(1),Sample identification and other information,New Jersey,East Brunswick,8816,United States,2012,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,11/16/2012,11,16,2012,Laboratory records do not include the source or location from where the sample was obtained.
806029,21 CFR 211.22(d),"Procedures not  in writing, fully followed",New Jersey,Sparta,7871,United States,2012,Drug Quality Assurance,NAI,"Akorn, Inc.",10/26/2012,10,26,2012,The responsibilities and procedures applicable to the quality control unit are not fully followed.
806029,21 CFR 211.188,"Prepared for each batch, include complete information",New York,Holtsville,11742,United States,2012,Drug Quality Assurance,VAI,"Akorn, Inc.",10/26/2012,10,26,2012,Batch production and control records do not include complete information relating to the production and control of each batch.
805292,21 CFR 314.80(b),Failure to develop written procedures,New York,Farmingdale,11735,United States,2012,Drug Quality Assurance,OAI,Pfizer Inc.,10/15/2012,10,15,2012,"Written procedures have not been developed for the surveillance, receipt, evaluation, and reporting to FDA of post marketing adverse drug experiences."
805292,21 CFR 314.80(b),Failure to review ADE information,New York,Farmingdale,11735,United States,2012,Unapproved and Misbranded Drugs,OAI,Pfizer Inc.,10/15/2012,10,15,2012,"Adverse drug experience information obtained or otherwise received from any source was not promptly reviewed, including information from commercial marketing experience."
805292,21 CFR 314.80(c)(1)(ii),"Failure to investigate serious, unexpected events",Florida,Miami,33169,United States,2012,Bioresearch Monitoring,VAI,Pfizer Inc.,10/15/2012,10,15,2012,Adverse drug experiences that were the subject of post marketing 15-day reports were not promptly investigated.
805292,21 CFR 314.80(c)(1)(ii),Submission of report follow-up,Washington,Bellingham,98226,United States,2012,Unapproved and Misbranded Drugs,NAI,Pfizer Inc.,10/15/2012,10,15,2012,Follow-up reports were not submitted within 15 calendar days of receipt of new information concerning post marketing 15-day reports.
805292,21 CFR 314.80(c)(1)(iii),Non-applicant reports to applicant,Delaware,Newark,19702,United States,2012,Drug Quality Assurance,NAI,Pfizer Inc.,10/15/2012,10,15,2012,"You, as a non-applicant, elected to submit to the applicant (rather than to FDA) all reports of adverse drug experiences that were both serious and unexpected. However, you did not submit each report to the applicant within five calendar days of your receipt of the information."
797913,21 CFR 211.42(c),Defined areas of adequate size for operations,New Jersey,Boonton,7005,United States,2012,Drug Quality Assurance,NAI,American Health Packaging,9/10/2012,9,10,2012,The separate or defined areas necessary to prevent contamination or mix-ups are deficient.
797913,21 CFR 211.80(d),Status of Each Lot Identified,New York,Poughkeepsie,12601,United States,2012,Bioresearch Monitoring,NAI,American Health Packaging,9/10/2012,9,10,2012,"Each lot of components, drug product containers, and closures was not appropriately identified as to its status in terms of being quarantined, approved or rejected."
798676,21 CFR 211.58,Buildings not maintained in good state of repair,New Jersey,North Brunswick,8902,United States,2012,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,8/31/2012,8,31,2012,Buildings used in the manufacturing of a drug product are not maintained in a good state of repair.
798676,21 CFR 211.110(b),In-process materials specifications,New Jersey,Parsippany,7054,United States,2012,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,8/31/2012,8,31,2012,"In-process specifications are not consistent with drug product final specifications, derived from previous acceptable process average and process variability estimates where possible, and determined by the application of suitable statistical procedures where appropriate."
798676,21 CFR 314.81(b)(1)(ii),"Contamination, chemical or physical change, deterioration",Wisconsin,Jackson,53037,United States,2012,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,8/31/2012,8,31,2012,"An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning significant chemical, physical, or other change or deterioration in a distributed drug product."
795558,21 CFR 211.22(a),"Authority lacking to review records, investigate errors",Washington,Mount Vernon,98273,United States,2012,Drug Quality Assurance,NAI,L. Perrigo Company,8/24/2012,8,24,2012,The quality control unit lacks authority to fully investigate errors that have occurred.
795558,21 CFR 211.192,"Investigations of discrepancies, failures",Utah,Salt Lake City,84132,United States,2012,Bioresearch Monitoring,VAI,L. Perrigo Company,8/24/2012,8,24,2012,There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
799252,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Michigan,Livonia,48150,United States,2011,Drug Quality Assurance,NAI,Apotex Inc.,8/24/2012,8,24,2012,The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
799252,21 CFR 211.25(a),GMP Training Frequency,Puerto Rico,Juncos,777,United States,2011,Drug Quality Assurance,VAI,Apotex Inc.,8/24/2012,8,24,2012,GMP training is not conducted with sufficient frequency to assure that employees remain familiar with CGMP requirements applicable to them.
799252,21 CFR 211.56(a),"Sanitation--buildings not clean, free of infestation",Indiana,Indianapolis,46211,United States,2011,Postmarket Surv. and Epidemiology,NAI,Apotex Inc.,8/24/2012,8,24,2012,"Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition."
799252,21 CFR 211.80(d),Status of Each Lot Identified,Oregon,Eugene,97401,United States,2011,Bioresearch Monitoring,VAI,Apotex Inc.,8/24/2012,8,24,2012,"Each lot of was not appropriately identified as to its status in terms of being quarantined, approved or rejected."
799252,21 CFR 211.103,Actual vs. theoretical yields not determined,New Jersey,Florham Park,7932,United States,2011,Postmarket Surv. and Epidemiology,NAI,Apotex Inc.,8/24/2012,8,24,2012,Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of processing of the drug product.
799252,21 CFR 211.125(d),Destruction of excess labels with lot numbers,Indiana,Indianapolis,46202,United States,2011,Bioresearch Monitoring,OAI,Apotex Inc.,8/24/2012,8,24,2012,Excess labeling bearing lot or control numbers is not destroyed.
803870,21 CFR 314.80(c)(1)(i),Late submission of 15-day report,Florida,Coral Gables,33134,United States,2011,Bioresearch Monitoring,VAI,"Lannett Company, Inc.",8/17/2012,8,17,2012,Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
803870,21 CFR 314.80(c)(1)(iii),Non-applicant reports directly to FDA,Michigan,Detroit,48202,United States,2011,Postmarket Surv. and Epidemiology,NAI,"Lannett Company, Inc.",8/17/2012,8,17,2012,"You, as a non-applicant, did not elect to submit to the applicant all reports of adverse drug experiences that were both serious and unexpected. You were therefore obligated to submit those reports directly to FDA, but you did not submit each report."
792357,21 CFR 211.100(a),Absence of Written Procedures,California,Huntington Beach,92646,United States,2011,Drug Quality Assurance,VAI,"Hospira, Inc.",7/26/2012,7,26,2012,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
792357,21 CFR 211.110(a),Control procedures to monitor and validate performance,California,Huntington Beach,92646,United States,2011,Unapproved and Misbranded Drugs,VAI,"Hospira, Inc.",7/26/2012,7,26,2012,Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
792357,21 CFR 314.81(b)(1)(ii),Failure to meet specifications,Washington,Tacoma,98405,United States,2011,Bioresearch Monitoring,NAI,"Hospira, Inc.",7/26/2012,7,26,2012,An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning a failure of one or more distributed batches of a drug to meet the specifications established for it in the application.
790064,21 CFR 211.87,Retest of approved components/containers/closures,Louisiana,Baton Rouge,70809,United States,2011,Drug Quality Assurance,OAI,"Lincare, Inc.",7/10/2012,7,10,2012,"Approved drug product containers are not retested or reexamined as appropriate for identity, strength, quality and purity after exposure to conditions that might have an adverse effect with subsequent approval or rejection by the quality control unit."
789123,21 CFR 211.22(a),Contract drug products--lack of responsibility,Montana,Helena,59061,United States,2011,Drug Quality Assurance,NAI,Baxter Healthcare Corporation,6/27/2012,6,27,2012,The quality control unit lacks responsibility for approving or rejecting drug products manufactured under contract by another company.
791750,21 CFR 211.100(b),Procedure Deviations Recorded and Justified,Tennessee,Nashville,37209,United States,2011,Drug Quality Assurance,NAI,Medline Industries Inc,6/21/2012,6,21,2012,Deviations from written production and process control procedures are not recorded and justified.
791750,21 CFR 211.192,"Extent of discrepancy, failure  investigations",Oklahoma,Yukon,73099,United States,2011,Bioresearch Monitoring,VAI,Medline Industries Inc,6/21/2012,6,21,2012,Investigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product.
792749,21 CFR 211.25(a),"Training--operations, GMPs, written procedures",Texas,Austin,78758,United States,2011,Drug Quality Assurance,NAI,"Aidapak Services, LLC",6/19/2012,6,19,2012,Employees are not given training in current good manufacturing practices and written procedures required by current good manufacturing practice regulations.
792749,21 CFR 211.28(a),Clothing appropriate for duties performed,New Jersey,Princeton,8543,United States,2011,Bioresearch Monitoring,VAI,"Aidapak Services, LLC",6/19/2012,6,19,2012,Clothing of personnel engaged in the packing and holding of drug products is not appropriate for the duties they perform.
792749,21 CFR 211.80(a),Written Procedures Not Followed,Maryland,Baltimore,21229,United States,2011,Bioresearch Monitoring,NAI,"Aidapak Services, LLC",6/19/2012,6,19,2012,"Written procedures are not followed for the receipt, identification, storage, handling, sampling, testing, approval, and rejection of drug product containers and closures."
787924,21 CFR 211.68(a),Calibration/Inspection/Checking not done,Texas,Brenham,77833,United States,2011,Drug Quality Assurance,NAI,"VistaPharm, Inc.",6/15/2012,6,15,2012,Routine checking of electronic equipment is not performed according to a written program designed to assure proper performance.
787924,21 CFR 211.188(b)(12),Documentation of Batch Investigations,Pennsylvania,Mechanicsburg,17050,United States,2011,Drug Quality Assurance,NAI,"VistaPharm, Inc.",6/15/2012,6,15,2012,The batch production and control records are deficient in that they do not include documentation of batch investigations performed.
787926,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Pennsylvania,Mechanicsburg,17050,United States,2011,Drug Quality Assurance,NAI,Lloyd Inc. of Iowa,6/15/2012,6,15,2012,The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
787926,21 CFR 211.25(c),Inadequate number of  personnel,Pennsylvania,Lititz,17543,United States,2011,Drug Quality Assurance,NAI,Lloyd Inc. of Iowa,6/15/2012,6,15,2012,"The number of qualified personnel is inadequate to perform and supervise the manufacture, processing, packing, and holding of each drug product."
787926,21 CFR 211.194(a),Complete test data included in records,Missouri,Mound City,64470,United States,2011,Drug Quality Assurance,VAI,Lloyd Inc. of Iowa,6/15/2012,6,15,2012,"Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards."
787926,21 CFR 211.198(a),Procedures to be written and followed,California,South San Francisco,94080,United States,2011,Postmarket Surv. and Epidemiology,VAI,Lloyd Inc. of Iowa,6/15/2012,6,15,2012,Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.
787926,21 CFR 314.81(b)(1)(ii),"Contamination, chemical or physical change, deterioration",California,Ventura,93003,United States,2011,Drug Quality Assurance,VAI,Lloyd Inc. of Iowa,6/15/2012,6,15,2012,"An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning significant chemical, physical, or other change or deterioration in a distributed drug product."
788106,21 CFR 211.80(a),Procedures To Be in Writing,Ohio,Bryan,43506,United States,2011,Drug Quality Assurance,VAI,"VistaPharm, Inc.",6/15/2012,6,15,2012,Written procedures are lacking which describe in sufficient detail the handling of components.
788106,21 CFR 211.100(b),SOPs not followed / documented,New Jersey,North Bergen,7047,United States,2011,Drug Quality Assurance,NAI,"VistaPharm, Inc.",6/15/2012,6,15,2012,Written production and process control procedures are not followed in the execution of production and process control functions.
788106,21 CFR 211.142,Written warehousing procedures established/followed,Idaho,Idaho Falls,83401,United States,2011,Drug Quality Assurance,VAI,"VistaPharm, Inc.",6/15/2012,6,15,2012,Procedures describing the warehousing of drug products are not established.
786253,21 CFR 211.25(a),"Training , Education , Experience overall",New York,Melville,11747,United States,2011,Drug Quality Assurance,VAI,"Akorn, Inc.",5/25/2012,5,25,2012,Employees engaged in the processing of a drug product lack the training and experience required to perform their assigned functions.
783890,21 CFR 211.130,"Procedures are written, and followed",Florida,Deerfield Beach,33441,United States,2011,Unapproved and Misbranded Drugs,NAI,"Blenheim Pharmacal, Inc.",5/18/2012,5,18,2012,Procedures designed to assure that correct labels are used for drug products are not followed.
783890,21 CFR 211.130(e),Packaging line inspection before use,Utah,West Haven,84401,United States,2011,Unapproved and Misbranded Drugs,VAI,"Blenheim Pharmacal, Inc.",5/18/2012,5,18,2012,Inspection of the packaging facilities immediately before use is not done to assure that all drug products have been removed from previous operations.
783661,21 CFR 310.305(c)(1)(i),Late submission,Florida,Boca Raton,33487,United States,2011,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",5/4/2012,5,4,2012,Each post marketing 15-day Alert report was not submitted to FDA within 15 calendar days of initial receipt of the information.
783661,21 CFR 314.80(c)(2),Late submission of annual safety reports,South Carolina,Goose Creek,29445,United States,2011,Drug Quality Assurance,VAI,"Fresenius Kabi USA, LLC",5/4/2012,5,4,2012,Not all annual periodic adverse drug experience reports have been submitted within 60 days of the anniversary date of the approval of the application.
774592,21 CFR 211.100(a),Absence of Written Procedures,Florida,Miami,33136,United States,2011,Bioresearch Monitoring,OAI,"TG United, Inc.",3/30/2012,3,30,2012,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
774592,21 CFR 211.180(e)(2),Items to cover on annual reviews,Ohio,Akron,44301,United States,2011,Drug Quality Assurance,NAI,"TG United, Inc.",3/30/2012,3,30,2012,"Written procedures are not followed for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product."
775379,21 CFR 211.100(a),Absence of Written Procedures,Missouri,Saint Peters,63376,United States,2011,Drug Quality Assurance,NAI,"TG United, Inc.",3/30/2012,3,30,2012,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
775379,21 CFR 211.166(b),Adequate number of batches on stability,Missouri,Saint Louis,63118,United States,2011,Drug Quality Assurance,VAI,"TG United, Inc.",3/30/2012,3,30,2012,An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
775379,21 CFR 211.180(e)(2),Items to cover on annual reviews,Virginia,Alexandria,22312,United States,2011,Drug Quality Assurance,OAI,"TG United, Inc.",3/30/2012,3,30,2012,"Written procedures are not followed for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product."
775379,21 CFR 211.192,Written record of investigation incomplete,New Jersey,Princeton,8540,United States,2011,Postmarket Surv. and Epidemiology,NAI,"TG United, Inc.",3/30/2012,3,30,2012,Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not include the conclusions and follow-up.
775386,21 CFR 211.160(b)(4),"Calibration - at intervals, written program, remedial action",Minnesota,Cambridge,55008,United States,2011,Drug Quality Assurance,VAI,"TG United, Inc.",3/30/2012,3,30,2012,"The calibration of instruments, apparatus, gauges, and recording devices is not done at suitable intervals in accordance with an established written program."
775386,21 CFR 211.165(a),Testing and release for distribution,California,San Dimas,91773,United States,2011,Drug Quality Assurance,NAI,"TG United, Inc.",3/30/2012,3,30,2012,Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
775386,21 CFR 211.166(b),Adequate number of batches on stability,Ohio,Solon,44139,United States,2011,Drug Quality Assurance,NAI,"TG United, Inc.",3/30/2012,3,30,2012,An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
775386,21 CFR 211.192,Written record of investigation incomplete,Florida,Orlando,32837,United States,2011,Drug Quality Assurance,NAI,"TG United, Inc.",3/30/2012,3,30,2012,Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not include the conclusions and follow-up.
775386,21 CFR 211.194(b),Test method modification records not maintained,Kentucky,Florence,41042,United States,2011,Drug Quality Assurance,NAI,"TG United, Inc.",3/30/2012,3,30,2012,Complete records are not maintained of any modification of an established method employed in testing.
771513,21 CFR 211.46(b),Equipment for Environmental Control,Florida,North Palm Beach,33408,United States,2011,Bioresearch Monitoring,OAI,Product Quest Manufacturing LLC,3/11/2012,3,11,2012,"Equipment for adequate control over humidity and temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product."
771513,21 CFR 211.100(a),Absence of Written Procedures,New York,Williamsville,14221,United States,2011,Bioresearch Monitoring,NAI,Product Quest Manufacturing LLC,3/11/2012,3,11,2012,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
771513,21 CFR 211.160(b)(4),"Calibration - at intervals, written program, remedial action",New Jersey,Buena,8310,United States,2011,Drug Quality Assurance,VAI,Product Quest Manufacturing LLC,3/11/2012,3,11,2012,The calibration of instruments and apparatus is not done at suitable intervals in accordance with an established written program.
771513,21 CFR 211.166(a),Written program not followed,California,Carson,90746,United States,2011,Drug Quality Assurance,NAI,Product Quest Manufacturing LLC,3/11/2012,3,11,2012,The written stability testing program is not followed.
771666,21 CFR 211.192,"Investigations of discrepancies, failures",Colorado,Denver,80239,United States,2011,Drug Quality Assurance,VAI,"Hospira, Inc.",3/9/2012,3,9,2012,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
769594,21 CFR 314.80(c)(1)(i),Late submission of 15-day report,New Jersey,North Bergen,7047,United States,2011,Drug Quality Assurance,VAI,"Taro Pharmaceuticals U.S.A., Inc.",3/8/2012,3,8,2012,Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
769594,21 CFR 314.80(f)(1),Wrong form - domestic ADE,California,Pleasanton,94566,United States,2011,Drug Quality Assurance,OAI,"Taro Pharmaceuticals U.S.A., Inc.",3/8/2012,3,8,2012,An FDA Form 3500A has not been completed for each report of a domestic adverse drug experience.
772764,21 CFR 211.110(a),Written in-process control procedures,West Virginia,Charleston,25304,United States,2011,Bioresearch Monitoring,VAI,Cadila Healthcare Limited,2/23/2012,2,23,2012,Written procedures are not established that describe the tests and examinations to be conducted on appropriate samples of in-process materials of each batch.
772764,21 CFR 211.113(a),Procedures for non-sterile drug products,California,Sacramento,95821,United States,2011,Bioresearch Monitoring,VAI,Cadila Healthcare Limited,2/23/2012,2,23,2012,Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established.
772764,21 CFR 211.113(b),Procedures for sterile drug products,Texas,Amarillo,79106,United States,2011,Drug Quality Assurance,NAI,Cadila Healthcare Limited,2/23/2012,2,23,2012,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
772764,21 CFR 211.160(a),Following/documenting laboratory controls,Texas,Amarillo,79101,United States,2011,Drug Quality Assurance,NAI,Cadila Healthcare Limited,2/23/2012,2,23,2012,Established laboratory control mechanisms are not followed and documented at the time of performance.
772764,21 CFR 211.165(e),Test methods,Texas,Dallas,75211,United States,2011,Drug Quality Assurance,VAI,Cadila Healthcare Limited,2/23/2012,2,23,2012,The accuracy and sensitivity of test methods have not been established.
771045,21 CFR 211.42(c)(5),Mfg / Processing Operations Area,Georgia,Alpharetta,30005,United States,2011,Drug Quality Assurance,NAI,Aidarex Pharmaceuticals LLC,2/22/2012,2,22,2012,Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
771045,21 CFR 211.46(b),Equipment for Environmental Control,Pennsylvania,Allentown,18102,United States,2011,Drug Quality Assurance,OAI,Aidarex Pharmaceuticals LLC,2/22/2012,2,22,2012,"Equipment for adequate control over air pressure is not provided when appropriate for the manufacture, processing, packing or holding of a drug product."
771045,21 CFR 211.63,"Equipment Design, Size and Location",Texas,Sugar Land,77478,United States,2011,Drug Quality Assurance,NAI,Aidarex Pharmaceuticals LLC,2/22/2012,2,22,2012,"Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance."
771045,21 CFR 211.176,Failing to test for penicillin cross-contamination,Indiana,Indianapolis,46290,United States,2011,Bioresearch Monitoring,OAI,Aidarex Pharmaceuticals LLC,2/22/2012,2,22,2012,"Non-penicillin drug products were not tested for the presence of penicillin, when a reasonable possibility existed that a non-penicillin drug product has been exposed to a cross-contamination with penicillin."
767603,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Pennsylvania,Mechanicsburg,17055,United States,2011,Drug Quality Assurance,NAI,Mylan Pharmaceuticals Inc.,2/2/2012,2,2,2012,The responsibilities and procedures applicable to the quality control unit are not in writing.
767603,21 CFR 211.42(c),Defined areas of adequate size for operations,New Jersey,Ridgefield,7657,United States,2011,Drug Quality Assurance,VAI,Mylan Pharmaceuticals Inc.,2/2/2012,2,2,2012,The separate or defined areas necessary to prevent contamination or mix-ups are deficient.
767603,21 CFR 211.42(c)(5),Mfg / Processing Operations Area,Illinois,Libertyville,60048,United States,2011,Drug Quality Assurance,NAI,Mylan Pharmaceuticals Inc.,2/2/2012,2,2,2012,Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
764997,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Washington,Seattle,98108,United States,2011,Bioresearch Monitoring,OAI,Novartis Pharmaceuticals Corp.,1/31/2012,1,31,2012,The responsibilities and procedures applicable to the quality control unit are not fully followed.
764997,21 CFR 211.111,Establishment of time limitations,Florida,Sarasota,34243,United States,2011,Drug Quality Assurance,NAI,Novartis Pharmaceuticals Corp.,1/31/2012,1,31,2012,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
764997,21 CFR 211.186(b)(7),Theoretical yield statement including percentages,Missouri,Kennett,63857,United States,2011,Drug Quality Assurance,NAI,Novartis Pharmaceuticals Corp.,1/31/2012,1,31,2012,Master production and control records lack a statement of theoretical yield including the maximum and minimum percentages of theoretical yield beyond which investigation is required.
761230,21 CFR 314.80(c)(1)(i),Late submission of 15-day report,Washington,Spokane,99207,United States,2011,Drug Quality Assurance,NAI,Lupin Pharmaceuticals Inc.,12/23/2011,12,23,2011,Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
761230,21 CFR 314.80(c)(2),Late submission of quarterly safety reports,Michigan,Grand Rapids,49512,United States,2011,Drug Quality Assurance,VAI,Lupin Pharmaceuticals Inc.,12/23/2011,12,23,2011,Not all quarterly periodic adverse drug experience reports have been submitted within 30 days of the close of the quarter.
757254,21 CFR 211.68(a),Calibration/Inspection/Checking not done,Florida,Winter Park,32789,United States,2011,Bioresearch Monitoring,VAI,"Lincare, Inc.",12/16/2011,12,16,2011,Routine calibration of electronic equipment is not performed according to a written program designed to assure proper performance.
757254,21 CFR 211.188(b)(2),Identity of major equipment and lines used,Alabama,Birmingham,35205,United States,2011,Bioresearch Monitoring,VAI,"Lincare, Inc.",12/16/2011,12,16,2011,Batch production and control records do not include the identity of individual major equipment used for each batch of drug product produced.
757254,21 CFR 211.192,"Investigations of discrepancies, failures",Indiana,Columbus,47201,United States,2011,Drug Quality Assurance,VAI,"Lincare, Inc.",12/16/2011,12,16,2011,There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
757254,21 CFR 211.192,Quality control unit review of records,Indiana,Columbus,47201,United States,2011,Drug Quality Assurance,VAI,"Lincare, Inc.",12/16/2011,12,16,2011,"Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed."
753908,21 CFR 211.192,"Investigations of discrepancies, failures",North Carolina,Marion,28752,United States,2010,Drug Quality Assurance,NAI,Sage Products Inc,11/9/2011,11,9,2011,There is a failure to thoroughly review whether or not the batch has been already distributed.
752297,21 CFR 211.160(b),Scientifically sound laboratory controls,Texas,Carrollton,75006,United States,2010,Drug Quality Assurance,VAI,Baxter Healthcare Corporation,11/3/2011,11,3,2011,"Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity."
752879,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Maryland,Frederick,21704,United States,2010,Drug Quality Assurance,VAI,GlaxoSmithKline LLC,11/2/2011,11,2,2011,The responsibilities and procedures applicable to the quality control unit are not fully followed.
738828,21 CFR 314.80(c)(1)(i),Late submission of 15-day report,Pennsylvania,Wayne,19087,United States,2010,Drug Quality Assurance,NAI,Apotex Corp.,8/10/2011,8,10,2011,Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
738907,21 CFR 211.25(a),"Training , Education , Experience overall",Pennsylvania,Wayne,19087,United States,2010,Postmarket Surv. and Epidemiology,NAI,King Bio Inc.,8/10/2011,8,10,2011,Employees engaged in the processing of a drug product lack the education and training required to perform their assigned functions.
738907,21 CFR 211.84(e),Rejecting  When Specifications Not Met,Tennessee,Nashville,37210,United States,2010,Drug Quality Assurance,NAI,King Bio Inc.,8/10/2011,8,10,2011,"Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity."
738907,21 CFR 211.165(b),Microbiological testing,California,San Diego,92121,United States,2010,Drug Quality Assurance,VAI,King Bio Inc.,8/10/2011,8,10,2011,Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
738907,21 CFR 211.166(a),Written program not followed,New Hampshire,Salem,3079,United States,2010,Drug Quality Assurance,NAI,King Bio Inc.,8/10/2011,8,10,2011,The written stability testing program is not followed.
738907,21 CFR 211.186(b)(9),Manufacturing Instructions and Specifications,Missouri,Columbia,65201,United States,2010,Drug Quality Assurance,NAI,King Bio Inc.,8/10/2011,8,10,2011,The master production and control records are deficient in that they do not include complete testing and procedures.
738907,21 CFR 211.192,Quality control unit review of records,Missouri,Columbia,65202,United States,2010,Drug Quality Assurance,NAI,King Bio Inc.,8/10/2011,8,10,2011,"Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed."
732653,21 CFR 211.56(a),"Sanitation--buildings not clean, free of infestation",Massachusetts,Wilmington,1887,United States,2010,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,"Buildings used in the manufacture, processing, packing or holding of drug products are not free of infestation by rodents, birds insects, and other vermin."
732653,21 CFR 211.63,"Equipment Design, Size and Location",Nevada,Las Vegas,89123,United States,2010,Bioresearch Monitoring,VAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,"Equipment used in the manufacture, processing, packing or holding of drug products is not suitably located to facilitate operations for its intended use."
732653,21 CFR 211.68(b),input/output verification,Pennsylvania,West Reading,19611,United States,2010,Drug Quality Assurance,VAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,Input to and output from the computer and related systems of formulas are not checked for accuracy.
732653,21 CFR 211.84(d)(3),Container/Closure Written Test Procedure,Alabama,Huntsville,35811,United States,2010,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,Drug product container and closure test procedures are deficient in that containers are not tested for conformance in accordance with appropriate written procedures.
732653,21 CFR 211.113(b),Procedures for sterile drug products,Ohio,Columbus,43201,United States,2010,Bioresearch Monitoring,NAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not written and followed.
732653,21 CFR 211.113(b),Validation lacking for sterile drug products,Wisconsin,Franklin,53132,United States,2010,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
732653,21 CFR 211.160(b),Scientifically sound laboratory controls,Florida,Jacksonville,32256,United States,2010,Bioresearch Monitoring,VAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,"Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity."
732653,21 CFR 211.165(d),Acceptance criteria for sampling & testing,California,Novato,94949,United States,2010,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release.
732653,21 CFR 211.170(b),Annual visual exams of drug products,Pennsylvania,West Hazleton,18202,United States,2010,Drug Quality Assurance,NAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
732653,21 CFR 211.186(a),Written procedures followed,North Carolina,Farmville,27828,United States,2010,Drug Quality Assurance,VAI,"Fresenius Kabi USA, LLC",7/8/2011,7,8,2011,Procedures for the preparation of master production and control records are not followed.
730740,21 CFR 211.42(c),Defined areas of adequate size for operations,Florida,Tampa,33618,United States,2010,Bioresearch Monitoring,VAI,"Genentech, Inc.",6/23/2011,6,23,2011,The control systems necessary to prevent contamination or mix-ups are deficient.
730740,21 CFR 211.42(c)(10),Aseptic Processing Area,Louisiana,Hahnville,70057,United States,2010,Drug Quality Assurance,NAI,"Genentech, Inc.",6/23/2011,6,23,2011,Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.
730740,21 CFR 211.113(b),Validation lacking for sterile drug products,California,Brisbane,94005,United States,2010,Bioresearch Monitoring,VAI,"Genentech, Inc.",6/23/2011,6,23,2011,Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
730740,21 CFR 211.160(a),Following/documenting laboratory controls,Virginia,Falls Church,22042,United States,2010,Bioresearch Monitoring,NAI,"Genentech, Inc.",6/23/2011,6,23,2011,Established laboratory control mechanisms are not followed.
730740,21 CFR 211.192,No written record of investigation,Wisconsin,Madison,53715,United States,2010,Bioresearch Monitoring,VAI,"Genentech, Inc.",6/23/2011,6,23,2011,Written records are not always made of investigations into unexplained discrepancies.
730740,21 CFR 211.192,Written record of investigation incomplete,North Carolina,Rockwell,28138,United States,2010,Drug Quality Assurance,NAI,"Genentech, Inc.",6/23/2011,6,23,2011,Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not include the conclusions and follow-up.
730684,21 CFR 211.122(a),Written procedures not followed,California,Anaheim,92804,United States,2010,Bioresearch Monitoring,VAI,"Blenheim Pharmacal, Inc.",6/17/2011,6,17,2011,Written procedures for the handling of packaging and labeling materials are not followed.
730684,21 CFR 211.184(e),Records of disposition of rejected material,Texas,San Antonio,78233,United States,2010,Drug Quality Assurance,VAI,"Blenheim Pharmacal, Inc.",6/17/2011,6,17,2011,Records do not include the disposition of rejected drug product containers.
727159,21 CFR 211.68(b),Computer control of master formula records,New Jersey,Paulsboro,8066,United States,2010,Drug Quality Assurance,NAI,L'Oreal USA Products Inc,5/25/2011,5,25,2011,Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
714961,21 CFR 211.67(b),Written procedures not established/followed,New Hampshire,Bedford,3110,United States,2009,Drug Quality Assurance,VAI,"Lannett Company, Inc.",3/21/2011,3,21,2011,"Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product."
714961,21 CFR 211.111,Establishment of time limitations,Florida,Miami,33175,United States,2009,Bioresearch Monitoring,VAI,"Lannett Company, Inc.",3/21/2011,3,21,2011,Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
714961,21 CFR 211.192,"Investigations of discrepancies, failures",Illinois,Chicago,60623,United States,2009,Drug Quality Assurance,VAI,"Lannett Company, Inc.",3/21/2011,3,21,2011,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
712034,21 CFR 211.22(d),"Procedures not  in writing, fully followed",Wisconsin,Germantown,53022,United States,2009,Drug Quality Assurance,VAI,Carilion Materials Management,3/2/2011,3,2,2011,The responsibilities and procedures applicable to the quality control unit are not in writing.
712034,21 CFR 211.25(a),"Training--operations, GMPs, written procedures",Wisconsin,Germantown,53022,United States,2009,Drug Quality Assurance,VAI,Carilion Materials Management,3/2/2011,3,2,2011,"Employees are not given training in the particular operations they perform as part of their function, current good manufacturing practices, and written procedures required by current good manufacturing practice regulations."
712034,21 CFR 211.42(c),Defined areas of adequate size for operations,New York,Glendale,11385,United States,2009,Drug Quality Assurance,NAI,Carilion Materials Management,3/2/2011,3,2,2011,The separate or defined areas necessary to prevent contamination or mix-ups are deficient.
712034,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Ohio,Cleveland,44106,United States,2009,Drug Quality Assurance,VAI,Carilion Materials Management,3/2/2011,3,2,2011,"Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
712034,21 CFR 211.80(a),Procedures To Be in Writing,California,Valencia,91355,United States,2009,Bioresearch Monitoring,NAI,Carilion Materials Management,3/2/2011,3,2,2011,"Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, approval, and rejection of components and drug product containers."
712034,21 CFR 211.125(a),Strict control not exercised over labeling issued,New York,New York,10065,United States,2009,Bioresearch Monitoring,NAI,Carilion Materials Management,3/2/2011,3,2,2011,Strict control is not exercised over labeling issued for use in drug product labeling operations.
712034,21 CFR 211.182,Written records kept in individual logs,California,San Diego,92126,United States,2009,Drug Quality Assurance,NAI,Carilion Materials Management,3/2/2011,3,2,2011,"Written records of major equipment cleaning, maintenance, and use are not included in individual equipment logs."
712034,21 CFR 211.188,"Prepared for each batch, include complete information",California,San Francisco,94111,United States,2009,Drug Quality Assurance,NAI,Carilion Materials Management,3/2/2011,3,2,2011,Batch production and control records do not include complete information relating to the production and control of each batch.
712034,21 CFR 211.188(b)(6),Inspection of packaging and labeling area,California,Carmichael,95608,United States,2009,Bioresearch Monitoring,NAI,Carilion Materials Management,3/2/2011,3,2,2011,Batch production and control records do not include results of the inspection of the packaging and labeling area before and after use for each batch of drug product produced.
712034,21 CFR 211.188(b)(10),Records of any sampling performed,Connecticut,Rocky Hill,6067,United States,2009,Bioresearch Monitoring,VAI,Carilion Materials Management,3/2/2011,3,2,2011,"Batch production and control records do not include a record of any sampling performed, for each batch of drug product produced."
712034,21 CFR 211.192,Quality control unit review of records,Missouri,Brentwood,63144,United States,2009,Drug Quality Assurance,VAI,Carilion Materials Management,3/2/2011,3,2,2011,"Drug product production and control records, are not reviewed by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed."
712034,21 CFR 211.198(a),Complaint Handling Procedure,Missouri,Brentwood,63144,United States,2009,Postmarket Surv. and Epidemiology,VAI,Carilion Materials Management,3/2/2011,3,2,2011,Procedures describing the handling of written and oral complaints related to drug products are not written or followed.
710971,21 CFR 314.80(b),Failure to review ADE information,South Carolina,Beech Island,29842,United States,2009,Drug Quality Assurance,NAI,Zydus Pharmaceuticals USA Inc,2/22/2011,2,22,2011,"Adverse drug experience information obtained or otherwise received from any source was not reviewed, including information from commercial marketing experience."
711251,21 CFR 211.100(a),Absence of Written Procedures,Colorado,Denver,80239,United States,2009,Drug Quality Assurance,VAI,"Noven Pharmaceuticals, Inc.",2/14/2011,2,14,2011,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
711251,21 CFR 211.103,Actual vs. theoretical yields not determined,Ohio,Solon,44139,United States,2009,Drug Quality Assurance,NAI,"Noven Pharmaceuticals, Inc.",2/14/2011,2,14,2011,"Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of manufacturing, processing, packaging, and holding of the drug product."
711251,21 CFR 211.122(d),Label storage access limited to authorized personnel,Massachusetts,Woburn,1801,United States,2009,Drug Quality Assurance,VAI,"Noven Pharmaceuticals, Inc.",2/14/2011,2,14,2011,Access to the storage area for labels and labeling materials is not limited to authorized personnel.
711251,21 CFR 211.180(e)(2),Items to cover on annual reviews,Massachusetts,North Billerica,1862,United States,2009,Drug Quality Assurance,VAI,"Noven Pharmaceuticals, Inc.",2/14/2011,2,14,2011,"Written procedures are not followed for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product."
711251,21 CFR 211.192,"Investigations of discrepancies, failures",Massachusetts,Lexington,2421,United States,2009,Bioresearch Monitoring,NAI,"Noven Pharmaceuticals, Inc.",2/14/2011,2,14,2011,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
709477,21 CFR 211.100(b),SOPs not followed / documented,District of Columbia,Washington,20037,United States,2009,Bioresearch Monitoring,NAI,Cadila Healthcare Limited,2/3/2011,2,3,2011,Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.
705885,21 CFR 211.25(a),"Training--operations, GMPs, written procedures",Alabama,Homewood,35209,United States,2009,Drug Quality Assurance,OAI,"Aidapak Services, LLC",1/6/2011,1,6,2011,Employees are not given training in current good manufacturing practices and written procedures required by current good manufacturing practice regulations.
705885,21 CFR 211.42(c),Defined areas of adequate size for operations,Vermont,Bennington,5201,United States,2009,Bioresearch Monitoring,NAI,"Aidapak Services, LLC",1/6/2011,1,6,2011,The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.
705885,21 CFR 211.67(a),Cleaning / Sanitizing / Maintenance,Florida,Ocala,34474,United States,2009,Bioresearch Monitoring,VAI,"Aidapak Services, LLC",1/6/2011,1,6,2011,"Equipment and utensils are not cleaned, maintained, and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
705885,21 CFR 211.125(f),Procedures Written and Followed,Alabama,Montgomery,36106,United States,2009,Bioresearch Monitoring,NAI,"Aidapak Services, LLC",1/6/2011,1,6,2011,Procedures describing in sufficient detail the controls employed for the issuance of labeling are not followed.
705885,21 CFR 211.166(a),Lack of written stability program,Virginia,Charlottesville,22902,United States,2009,Drug Quality Assurance,VAI,"Aidapak Services, LLC",1/6/2011,1,6,2011,There is no written testing program designed to assess the stability characteristics of drug products.
705885,21 CFR 211.176,Failing to test for penicillin cross-contamination,New Hampshire,Salem,3079,United States,2009,Drug Quality Assurance,VAI,"Aidapak Services, LLC",1/6/2011,1,6,2011,"Non-penicillin drug products were not tested for the presence of penicillin, when a reasonable possibility existed that a non-penicillin drug product has been exposed to a cross-contamination with penicillin."
704290,21 CFR 211.100(a),Absence of Written Procedures,Connecticut,Terryville,6786,United States,2009,Drug Quality Assurance,VAI,Novartis Pharmaceuticals Corp.,12/21/2010,12,21,2010,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
704290,21 CFR 211.100(a),Approval and review of procedures,Texas,San Antonio,78229,United States,2009,Bioresearch Monitoring,NAI,Novartis Pharmaceuticals Corp.,12/21/2010,12,21,2010,"Written procedures are not drafted, reviewed and approved by the appropriate organizational units and reviewed and approved by the quality control unit."
704290,21 CFR 211.100(b),SOPs not followed / documented,California,Thousand Oaks,91320,United States,2009,Bioresearch Monitoring,NAI,Novartis Pharmaceuticals Corp.,12/21/2010,12,21,2010,Written production and process control procedures are not followed in the execution of production and process control functions.
704290,21 CFR 211.110(c),In-process materials characteristics testing,New York,Syracuse,13202,United States,2009,Drug Quality Assurance,NAI,Novartis Pharmaceuticals Corp.,12/21/2010,12,21,2010,"In-process materials are not tested for identity, strength, quality, and purity and approved or rejected by the quality control unit during the production process and after storage for long periods."
704290,21 CFR 211.166(a),"Results not used for expiration dates, storage cond.",New York,Norwich,13815,United States,2009,Drug Quality Assurance,NAI,Novartis Pharmaceuticals Corp.,12/21/2010,12,21,2010,Results of stability testing are not used in determining appropriate storage conditions and expiration dates.
704290,21 CFR 211.166(a),Written program not followed,Missouri,Creve Coeur,63141,United States,2009,Bioresearch Monitoring,NAI,Novartis Pharmaceuticals Corp.,12/21/2010,12,21,2010,The written stability testing program is not followed.
704290,21 CFR 211.188(b)(6),Inspection of packaging and labeling area,North Carolina,Kernersville,27284,United States,2009,Drug Quality Assurance,VAI,Novartis Pharmaceuticals Corp.,12/21/2010,12,21,2010,Batch production and control records do not include results of the inspection of the packaging and labeling area after use for each batch of drug product produced.
704290,21 CFR 211.192,"Investigations of discrepancies, failures",Texas,Fort Worth,76155,United States,2009,Drug Quality Assurance,VAI,Novartis Pharmaceuticals Corp.,12/21/2010,12,21,2010,There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
704290,21 CFR 211.198(a),Procedures to be written and followed,Texas,Dallas,75244,United States,2009,Drug Quality Assurance,NAI,Novartis Pharmaceuticals Corp.,12/21/2010,12,21,2010,Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.
701986,21 CFR 211.198(a),Procedures to be written and followed,Indiana,Jeffersonville,47130,United States,2009,Bioresearch Monitoring,VAI,Merck Sharp & Dohme Corp.,12/15/2010,12,15,2010,Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.
703036,21 CFR 211.192,Written record of investigation incomplete,Massachusetts,Devens,1434,United States,2009,Drug Quality Assurance,NAI,Teva Pharmaceuticals USA,12/2/2010,12,2,2010,Written records of investigations into unexplained discrepancies do not include the conclusions and follow-up.
703036,21 CFR 314.81(b)(1)(ii),Failure to meet specifications,Pennsylvania,Bethlehem,18020,United States,2009,Drug Quality Assurance,VAI,Teva Pharmaceuticals USA,12/2/2010,12,2,2010,An NDA-Field Alert Report was not submitted within three working days of receipt of information concerning a failure of one or more distributed batches of a drug to meet the specifications established for it in the application.
702473,21 CFR 211.160(b),Scientifically sound laboratory controls,New Jersey,Piscataway,8854,United States,2009,Drug Quality Assurance,NAI,"TG United, Inc.",11/24/2010,11,24,2010,"Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity."
702473,21 CFR 211.160(b)(4),"Calibration - at intervals, written program, remedial action",New York,Suffern,10901,United States,2009,Drug Quality Assurance,VAI,"TG United, Inc.",11/24/2010,11,24,2010,"The calibration of instruments, apparatus, and recording devices is not done at suitable intervals in accordance with an established written program."
702473,21 CFR 211.166(b),Adequate number of batches on stability,North Carolina,Kings Mountain,28086,United States,2009,Drug Quality Assurance,NAI,"TG United, Inc.",11/24/2010,11,24,2010,An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
702476,21 CFR 211.160(b),Scientifically sound laboratory controls,New Jersey,Totowa,7512,United States,2009,Drug Quality Assurance,VAI,"TG United, Inc.",11/24/2010,11,24,2010,"Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity."
702476,21 CFR 211.160(b)(4),"Calibration - at intervals, written program, remedial action",New Jersey,Totowa,7512,United States,2009,Drug Quality Assurance,VAI,"TG United, Inc.",11/24/2010,11,24,2010,"The calibration of instruments, apparatus, and recording devices is not done at suitable intervals in accordance with an established written program."
702476,21 CFR 211.166(b),Adequate number of batches on stability,North Carolina,Asheville,28803,United States,2009,Drug Quality Assurance,VAI,"TG United, Inc.",11/24/2010,11,24,2010,An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
702476,21 CFR 211.180(e)(2),Items to cover on annual reviews,New Jersey,Parsippany,7054,United States,2009,Bioresearch Monitoring,VAI,"TG United, Inc.",11/24/2010,11,24,2010,"Written procedures are not followed for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product."
702476,21 CFR 211.182,Written records kept in individual logs,Wisconsin,Madison,53704,United States,2009,Drug Quality Assurance,NAI,"TG United, Inc.",11/24/2010,11,24,2010,Written records of major equipment cleaning and use are not included in individual equipment logs.
702476,21 CFR 211.192,No written record of investigation,Minnesota,Minneapolis,55407,United States,2009,Bioresearch Monitoring,VAI,"TG United, Inc.",11/24/2010,11,24,2010,Written records are not always made of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications.
702476,21 CFR 211.192,Quality control unit review of records,Illinois,North Chicago,60064,United States,2009,Drug Quality Assurance,NAI,"TG United, Inc.",11/24/2010,11,24,2010,"Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed."
702487,21 CFR 211.100(a),Absence of Written Procedures,California,Northridge,91325,United States,2009,Bioresearch Monitoring,NAI,"TG United, Inc.",11/24/2010,11,24,2010,"There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess."
702487,21 CFR 211.160(b),Scientifically sound laboratory controls,Puerto Rico,Manati,674,United States,2009,Drug Quality Assurance,VAI,"TG United, Inc.",11/24/2010,11,24,2010,"Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity."
702487,21 CFR 211.160(b)(4),"Calibration - at intervals, written program, remedial action",Puerto Rico,Manati,674,United States,2009,Postmarket Surv. and Epidemiology,VAI,"TG United, Inc.",11/24/2010,11,24,2010,"The calibration of instruments, apparatus, and recording devices is not done at suitable intervals in accordance with an established written program."
702487,21 CFR 211.166(b),Adequate number of batches on stability,New Jersey,Raritan,8869,United States,2009,Bioresearch Monitoring,VAI,"TG United, Inc.",11/24/2010,11,24,2010,An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.
702487,21 CFR 211.180(e)(2),Items to cover on annual reviews,Mississippi,Meridian,39301,United States,2009,Bioresearch Monitoring,OAI,"TG United, Inc.",11/24/2010,11,24,2010,"Written procedures are not followed for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product."
702487,21 CFR 211.192,No written record of investigation,New York,Cooperstown,13326,United States,2009,Bioresearch Monitoring,NAI,"TG United, Inc.",11/24/2010,11,24,2010,Written records are not always made of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications.
681269,21 CFR 211.160(a),Following/documenting laboratory controls,California,Valencia,91355,United States,2009,Drug Quality Assurance,NAI,"Lincare, Inc.",9/22/2010,9,22,2010,Established test procedures are not documented at the time of performance.
681269,21 CFR 211.188,"Prepared for each batch, include complete information",Puerto Rico,Juncos,777,United States,2009,Drug Quality Assurance,NAI,"Lincare, Inc.",9/22/2010,9,22,2010,Batch production and control records do not include complete information relating to the production and control of each batch.
681269,21 CFR 211.188(b)(12),Investigations made into any unexplained discrepancy,Iowa,Des Moines,50314,United States,2009,Bioresearch Monitoring,NAI,"Lincare, Inc.",9/22/2010,9,22,2010,"Batch production and control records do not include the results of any investigation made into any unexplained discrepancy, whether or not the batch of drug product had already been distributed."
678440,21 CFR 211.192,Quality control unit review of records,California,Walnut Creek,94597,United States,2009,Unapproved and Misbranded Drugs,VAI,"Akorn, Inc.",9/17/2010,9,17,2010,"Drug product production and control records, are not reviewed by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed."
678441,21 CFR 211.80(a),Procedures To Be in Writing,Florida,Clearwater,33755,United States,2009,Bioresearch Monitoring,VAI,"Akorn, Inc.",9/17/2010,9,17,2010,"Written procedures are lacking which describe in sufficient detail the testing, approval, and rejection of components, drug product containers, and closures."
678441,21 CFR 211.84(a),Components withheld from use pending release,Missouri,Kansas City,64120,United States,2009,Drug Quality Assurance,NAI,"Akorn, Inc.",9/17/2010,9,17,2010,"Each lot of components, drug product containers, and closures is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit."
678441,21 CFR 211.100(b),SOPs not followed / documented,Ohio,Cincinnati,45229,United States,2009,Bioresearch Monitoring,NAI,"Akorn, Inc.",9/17/2010,9,17,2010,Written production and process control procedures are not followed in the execution of production and process control functions.
678441,21 CFR 211.192,Written record of investigation incomplete,New York,S New Berlin,13843,United States,2009,Drug Quality Assurance,NAI,"Akorn, Inc.",9/17/2010,9,17,2010,Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
680379,21 CFR 211.130(e),Packaging line inspection before use,Rhode Island,Portsmouth,2871,United States,2009,Drug Quality Assurance,OAI,Novartis Pharmaceuticals Corp.,9/16/2010,9,16,2010,Inspection of the packaging and labeling facilities immediately before use is not done to assure that all drug products have been removed from previous operations.
679142,21 CFR 211.188,"Prepared for each batch, include complete information",California,Anaheim,92801,United States,2009,Bioresearch Monitoring,NAI,"Lincare, Inc.",9/8/2010,9,8,2010,Batch production and control records do not include complete information relating to the production and control of each batch.
